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ABSTRACT 
 Nanotechnology has been utilized widely in medical fields to improve the 
treatment and diagnosis of several diseases. One of the key players to drive medical 
nanotechnology forward is nanoparticles, which have been intensively studied and used 
as a tool for imaging, drug delivery, and disease treatments. Gold and iron oxide, 
undoubtedly, are on the short list of the nanoparticles used in medical nanotechnology 
due to their biocompatibility, tunable surface, and unique physico-chemical properties. 
In this dissertation, we developed novel nanostructures using gold, iron oxide 
nanoparticles and polymers for various applications including Janus motors, vaccine 
delivery, and controlled drug release.    
We generated an asymmetrical Janus nanostructure using thermo-cleavable 
polymer, gold, and iron oxide nanoparticles for photothermal enhancement and nano 
motors through an active rotational motion. Gold/iron oxide Janus nanoparticles (JNS) 
are developed by a seed-mediated self-assembly using a thermo-cleavable polymer 
facilitating the process. The formed JNS strongly displays an asymmetrical 
photothermal effect to activate a rotational motion and enhances photothermia resulting 
in significant cell killing effects under weak near-infrared (NIR) light exposure. In 
addition, the JNS displays distinct active rotational motion under NIR laser light due to 
	 xx	
the temperature gradient at its surface, which can be used potentially as Janus motors 
for drug delivery in the future. We next harnessed the same thermo-cleavable polymer 
used in JNS formation for controlled drug release under NIR laser light irradiation. The 
iron oxide nanoparticles (IONP) were first encapsulated in the thermo-cleavable 
polymeric micelles with doxorubicin (Dox), a chemotherapeutic drug. After NIR trigger, 
the polymer is cleaved due to heat transfer from the IONP resulting in the release of 
doxorubicin from the micelles. This study demonstrated that the thermo-cleavable 
polymer could be used as a smart material for controlled drug release.  
We also generated another type of secondary structure, a “gold/iron oxide 
nanosatellite”, using poly (g- methacryloxypropyl trimethoxysilane) -b- poly (ethylene 
oxide) polymer (MPS-b-PEO). This nanosatellite structure, in which IONP is a central 
core and surrounded by multiple gold nanoparticles as satellites, is used for delivering 
antigens and an adjuvant for HPV+ head and neck cancer treatment. These 
nanosatellites deliver high surface density of E7/E6 oncogenic peptides and cyclic- 
guanosine-adenosine monophosphate (cGAMP) adjuvant to antigen presenting cells 
(APC) and further activate type I interferon (IFN-I) response. The nanosatellite vaccine 
also promotes antigen specific CD8+ T cells to infiltrate the tumors and inhibits tumor 
growth in an HPV+ head and neck tumor model when used as a single therapy or in 
combination therapy with an anti PD-L1 antibody. Nanosatellites offer many advantages 
for antigenic peptide and adjuvant delivery such as having a larger surface area, higher 
antigenic peptide density, higher cell uptake, and lower systemic elimination. 
	 xxi	
This thesis presents the versatile developments and applications of gold/iron oxide 
nanostructures (Janus and Nanosatellite) which have advantages for drug and vaccine 
delivery in the future.	
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CHAPTER 1 
INTRODUCTION 
1.1 Nanoparticles 
A nanoparticle by definition refers to a particle that has a characteristic dimension 
from 1 to 100 nm and shows a unique property that is different from non-nanoscale 
particles with the similar chemical composition1,2. Nanoparticles can be made from 
diverse materials such as polymers, lipids, or inorganic metals. Among these materials, 
gold and iron oxide nanoparticles are on a short list due to their tunable surface, 
imaging property, photothermal property, and biocompatibility3,4. In this dissertation, we 
focus on gold and iron oxide nanoparticles used for photothermal effects, Janus motors, 
controlled release and biomolecular delivery.  
Iron oxide nanoparticles 
Iron oxide nanoparticles (IONP) or magnetic nanoparticles are mostly made of g-
Fe2O3 (maghemite) or Fe3O4 (magnetite), which have superparamagnetic properties 
when the size is small enough (< 15nm). IONP becomes a popular candidate for 
biomedical applications due to its excellent safety profile. Superpara iron oxide 
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nanoparticles (SPION) exhibit strong response under a magnetic field, which are very 
useful for magnetic resonance imaging(MRI) and magnetic hyperthermia5. The most 
common methods to synthesize SPION are coprecipitation and thermal decomposition. 
Although coprecipitation method is easy and can produce SPION in a large scale, the 
size distribution is relatively wide. While, thermal decomposition requires a more 
complicated method, the size distribution is well-controlled. Regardless of the synthesis 
approaches, the major problem of SPIONs is they are not stable without a suitable 
coating. They tend to aggregate in physiological media or under a strong magnetic 
field6. To solve this problem, stabilizers or surface coating are required to inhibit the 
SPION aggregation7. These stabilizers and coating, generally, create either electrostatic 
and/or steric repulsions among SPIONs.   
I. Surface functionalization 
	
There are several functional groups interacting with the surface of SPION to 
prevent them from agglomeration and also to further conjugation with drugs, peptides, 
DNA/RNA or another inorganic nanoparticles8. Most commonly used functional groups 
to react with the SPION include polysiloxanes, carboxylic acids, diols, and phosphonic 
acids (Figure 1.1)9. A large number of hydroxyl groups are generated from iron atoms 
when SPION is in an aqueous solution making them readily to react with the above 
mentioned functional groups. Phosphonic acid derivatives demonstrate the highest 
grafting density followed by carboxylic acid and glycerol respectively. Carboxyl groups 
can be easily removed by temperature or replaced with higher affinity ligands  such as 
phosphonic acid and alkoxysilanes10,11. Some coatings have been approved by Food 
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and Drug Administration (FDA) such as carboxy-dextran coated SPION (RESOVIST) for 
MRI12. Polyethylene glycol (PEG) with different molecular weights and functional groups 
are also widely used for SPION coating due to stealthy property. PEG can react with a 
variety of functional groups. For example, carboxylic acid-PEG coated SPION can be 
further modified with carbodiimide (EDC)-/sulfo N-hydoxysuccinimide (NHS) coupling 
chemistry for covalent linking of primary amine and carboxylic acid groups. The single 
dispersed SPION with suitable bi-functional groups are ready for further conjugations 
with other molecules such as peptides, DNA/RNA, antibodies, and inorganic metals, 
which helps expand the applications of SPION for targeted drug delivery and imaging. 
BSA coated SPION were conjugated with Arg-Gly-Asp (RGD) peptide to target avb3 
integrin on metastatic tumor and tumor endothelial cells via thiolated PEG13. Membrane 
translocation MPAP peptides and siRNA were conjugated on the surface of dextran 
coated SPION via heterobifunctional linkers, m-maleimidobenzoyl-N- 
hydroxysuccinimide ester (MBS) crosslinker for MRI and optical imaging14.  
Not only are the single dispersed SPIONs used for biomedical applications, 
clustered SPIONs such as micelles or liposomes are also applicable for delivery and 
theranostics. The size range of SPION liposome is 100- 5,000 nm in which SPION are 
inserted into lipid layer of the liposome or interact with hydrophobic polymers in micelles 
and form stable structures10. Palmityl-nitro DOPA-modified SPION were encapsulated in 
lipid bilayer of liposomes demonstrates the controlled release of calcein dye as a model 
drug under alternating magnetic field (AMF)15. Oleic coated SPIONs formed stable 
micelles after mixing d-a-Tocopheryl-co-poly(ethylene glycol) 1000 succinate or vitamin 
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E TPGS polymer, which have better cellular uptake and T2 mapped MRI in a xenograph 
mouse model16.  
II. Pharmacokinetics, toxicity and biodistribution of SPION 
	
Pharmacokinetics, toxicity and biodistribution of SPIONs are determined by 
several factors including size, surface charge, shape, and coating materials17. SPIONs 
are mostly considered biocompatible, which have good safety profiles. SPION can be 
physiologically metabolized and degraded into free iron ions resulting in the temporary 
increase of iron amount presenting in the serum. High dose of SPION can cause iron 
over load in the serum and show toxicity. Reticuloendothelial systems (RES) such as 
liver, lung, and spleen are the major organs uptaking SPION. Dextran-coated SPIONs 
were excreted through urine and feces after intravenous injection. In vivo data of 10 nm 
polyol-maghemite nanoparticles show that the nanoparticles mainly accumulated in rats’ 
liver, kidneys, and lungs, while brain and heart remain unaffected. 40% of the 
nanoparticles were removed from serum within 24 hours and 75% of the nanoparticles 
were excreted via urine within 72 hours18. However, in vitro data suggest that the 
toxicity levels are different across the cell types. The same concentration of SPION 
(2.25 mM) shows toxicity to human brain cells but compatibility with human kidney cells. 
The same study also demonstrates that positively charged SPIONs are more toxic than 
negatively charged SPIONs19.   
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Gold nanoparticles 
Gold nanoparticle (AuNP) is one of the oldest kinds of nanoparticles that was 
discovered and used in ancient medicines20. This noble metal exhibits vivid colors by 
nature, which makes it very attractive for investigation21. Beyond its beauty, AuNP 
possesses distinct properties such as surface plasmon resonance, photothermal effect, 
photodynamic effect, tunable surface, and ionizing radiation20,22–25.  
AuNP can be synthesized in many ways. The most commonly used techniques 
are Turkevich method, and Brust and Schriffin method. Turkevich used citrate as a 
reducing and stabilizing agent, yielding water soluble AuNP with the size ranging from 
16- 150 nm26–29. Brust and Schriffin developed a new way to synthesized alkanethiol-
stabilized AuNP with smaller diameter, 1.5-5 nm by using a two-step method. 
Tetraoctylammonium bromide (TOAB) is used as the phase transfer reagent and 
sodium borohydride (NaBH4) is used as the reducing agent30.    
Last decades, AuNPs have been developed in different morphology such as gold 
nanorod (AuNR), gold nanocage, and gold nanostar, or combined with different 
compositions such as silicon, iron oxide, or silver31. These unique shapes and 
compositions broaden the applications of AuNP-based materials. Gold nanorods 
(AuNR) and gold nanoshells (AuNS) display strong photothermal effect due to the 
decay of the plasmon resonances in Au nanocrystals24. Gold nanocages are useful for 
photoactivated drug release, in which a drug is encapsulated inside and released after 
near infrared laser light irradiation32. Gold nanostars exhibit distinct gyromagnetic 
scattering for enhanced optical contrast under a magnetic field33. The surface of AuNP 
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is ready for further conjugation. This session covers the surface functionalization of 
AuNP, its biodistribution, and some applications related to next chapters. 
   
I. Surface functionalization 
	
One of the most important reasons that AuNP gains a lot of attention in research 
is the ease of surface decoration. AuNP can be conjugated with several types of 
molecules such as peptides, oligo nucleotides, small molecular drugs, and metals. 
General functional groups interacting with AuNP include thiolate, dithiolate, 
dithiocarbamate, carboxylate, amine, selenide, phosephine, or isothiocyanate moieties. 
While thiol-based functional group has been commonly used for non-labile covalent 
bonding, amine and carboxylate groups are mostly used for acid-base labile 
conjugations. The chemisorption between thiol and Au happen quickly in millisecond to 
minutes. A variety of bifunctional crosslinkers are available for AuNP conjugation such 
as thiol-NHS, thiol-COOH, thiol-NH3, click thiol-azide, or thiol-alkyne. However, thiols 
can also rapidly form disulfide bonds among themselves34. Using protected thiol 
functional groups such as ortho-pyridyl disulfide (OPSS) or actylthio can minimize the 
self-interaction but deprotection is required before use35,36. Dithiothreitol (DTT) and tris 
(2-carboxyethyl) phosephine (TCEP) are common reagents to reduce the disulfide 
bonds or deprotect the protected thiol groups37. Peptides containing a free cysteine can 
directly conjugate onto the surface of AuNP38. Polyethylene glycol (PEG) with different 
molecular weights usually insert between bifunctional groups to help stabilize the 
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conjugated molecules and also make them more flexible allowing the molecules to 
rotate and fit the target sites better39.  
II. Pharmacokinetics, toxicity and biodistribution of AuNP 
	
Pharmacokinetics of AuNP has been intensively studied in both in vitro and in 
vivo models. Size, surface charge, shape, and coating are the key parameters 
determining the fate of the AuNP40. Many pieces of evidence show that AuNPs are 
internalized by liver macrophages, secreted through the bile, and eliminated through 
feces41.  
The correlation study between biodistribution and size of AuNP shows that after 
IV. injection of AuNP with the diameter 2-40 nm into mice, 90% of AuNP were found in 
macrophages in the liver and 10% in macrophages in the spleen42. The studies in mice 
and rats demonstrate the similar trend that the major organ uptaking AuNP is liver; 
however, the smaller size of the AuNP (10 nm) has higher distribution to kidney and 
brain than larger size of AuNP (50, 100, and 200 nm)43,44.  In other words, the smaller 
sizes of AuNP have higher diffusional displacement. Another study shows that 
ultrasmall AuNPs with 1.9 nm diameter have very rapid clearance from the serum. The 
gold concentration in the serum drops by half within 10 minutes after IV injection45. 
AuNPs also have different distribution in blood. Small AuNPs prefer to stay in serum, 
while large AuNPs interact with blood cells46. Sadauskas investigated long term 
biodistribution of 40 nm AuNP in mice. Interestingly, the gold content in the liver reduce 
by only 9% after 6 months of IV injection suggesting that AuNPs have long-term 
accumulation in the body. It is believed that the mechanism of AuNP elimination in liver 
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mainly happens in Kupffer cells. Neighboring Kupffer cells phagocytosed the Kupffer 
cells damaged by the AuNP47.   
In addition to size effect of AuNP, the surface coating is similarly important. It has 
been known that higher density of PEG coated on the surface of AuNP helps prolong 
the blood circulation of AuNP due to the reduction of protein absorption of the AuNP48. 
Comparing the excretion of 2 nm AuNP with different coating ligands shows that 
glutathione coating has the most renal clearance due to the best stability in blood 
compared to citrate and cystine coating21. However, the nanoparticles with the 
hydrodynamic diameter less than 6 nm can be totally eliminated through glomerular 
filtration regardless of surface charge, while the renal clearance of the nanoparticles 
with the hydrodynamic diameter 6-8 nm depends on the surface charges. Cationic 
nanoparticles have higher glomerular filtration than anionic particles45,49. Charge-
selective glomerular filtration is influenced by the negative charges of the capillary wall 
in the kidney preventing  the anionic nanoparticles to entry50 (figure 1.2). Sometimes, 
nanoparticle aggregation in physiological fluid can increase the overall size of the 
nanoparticles hence they will be uptake to the liver and excreted through feces51.   
Toxicity studies of AuNP have been widely explored. AuNPs are unlike bulk gold. 
They are more reactive and could be toxic at high concentrations. Smaller AuNP tends 
to be more toxic than larger size due to high reactivity and oxidative stress resulting in 
mitochondria damage52. LD50 of Au is 3.2 g/kg53,54. However, there are several factors 
needed to be considered such as size, charge, and coating materials as mentioned 
earlier. In vitro models cannot always predict in vivo results. Therefore, the use of AuNP 
is still limited in clinical practice and further studies need to be explored.    
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1.2 Photothermal effect of nanoparticles 
Photothermia results from photoexcitation leading to the partial or total 
production of heat 55. This phenomenon is more obvious in nanoscale metals such as 
gold, silver and magnetic particles. The coherent collective oscillation of electrons in the 
conduction band influences large surface electric fields, intensifying the radiative 
properties of those metals when interacting with resonant electromagnetic radiation. 
The strongly absorbed radiation then converts effectively into heat on a pico second 
time domain attributed to electro-phonon or phonon-phonon processes56.  This 
discovery allows researcher to utilize the photothermal effect in cancer treatments, in 
which photothermal contrast agents were administered into the body followed by a light 
trigger to raise local temperature at tumors. The cumulative heat in the tumors 
subsequently ablates the cancer cells by disrupting the cell membrane57–59. This method 
provides an alternative for chemotherapy in drug-resistant patients.  
In the first generation of AuNP, gold nanospheres were utilized for hyperthermia 
applications with the visible region of light approximately 514 nm, which is close to 
absorption spectrum of AuNP60. However, using the UV-VIS light is not favorable due to 
the serious skin damage in a real clinical setting. An alternative option is to employ 
near-infrared (NIR) light with the wavelength 650- 900 nm.  NIR is considered safer to 
use as it has far less skin damage and has low absorption by biological fluid including 
hemoglobin. Last decade, the attention has been shifted from gold nanospheres to gold 
nanorods, gold nanoshells, gold nanocages, and gold nanosphere clusters because 
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they can absorb the incident light in NIR region, which is more suitable for clinical use61 
(figure 1.3).  
J.L. West group from Rice university discovered Gold nanoshells (GNS) in 2003 
and proved that GNS raised the temperature significantly after 6 minutes of NIR laser 
irradiation resulting in irreversible tumor tissue damage62. Another candidate for 
photothermal therapy is gold nanorods (GNR), which was first developed by El-Sayed 
group at Georgia tech in 2005. The absorption wavelength of GNR depends upon the 
aspect ratios of the particle such as transverse and longitudinal axes. The transverse 
axis plays an important role in NIR light absorption56. The major challenge of GNR is the 
loss of its surface aspect ratio after long exposure to the NIR laser light. The longitudinal 
axis of GNR slowly melts and it subsequently reshapes to gold nanosphere, which 
absorbs the VIS light. However, the melting effect of GNR depends on the surface 
coating. PEG can help slow down the loss of the surface aspect of GNR63.  
In addition to Au-based nanoparticles, magnetic nanoparticles such as Fe3O4 
also demonstrate photothermal property. Kim et al first reported the use of SPION to 
produce heat under a pulse laser light at 532 nm64. Later, SPIONs with highly 
crystallinity were developed and able to absorb the NIR light. Chen et al showed that 
the orientation character along the (100) and (110) lattice planes of the SPIONs 
synthesized by thermal decomposition significantly contributes to the photothermal 
capability of SPION. The local temperature raised 33 °C from the beginning after 10 
minutes of NIR laser illumination65.  
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There are many materials currently being explored for photothermal effect 
including NIR dyes, carbon nanotubes, and polypyrrol. However, only Aurolase, gold 
nanoshells, has just completed the clinical trial for head and neck cancer treatment at 
the end of 2016. The long-term results need further investigation. An important 
challenge of photothermal therapy is the nanomaterials under the skin are not 
sufficiently sensitive to NIR laser. The penetration of NIR light is limited only 2 mm 
under skin; therefore, strong laser power is required66. The high laser power can cause 
damage to normal tissue leading to adverse effects, which hamper the use of PTT in 
clinical trials. In summary, new materials with high sensitivity for NIR laser light still need 
to be developed for better photothermal treatment.  
1.3 Secondary structures 
Secondary structures refer to the structures that form secondary self-assembly 
from secondary building blocks such as worm-like micelles, vesicular structures, 
hexagonal structures or liquid crystal structures (figure 1.4). The secondary self-
assembly is induced by either aggregation or crosslinking. The interaction between two 
secondary building blocks can be either attraction or repulsion. The direct secondary 
self-assembly can happen only the attraction > repulsion force. The molecular 
rearrangement follows the law of thermodynamics, obeying the energetics of each case; 
therefore, the secondary structures can appear in several forms67. A systematic analysis 
of the structures of the building blocks is a crucial parameter to govern the self-
assembled aggregates regardless of their structural hierarchies. The secondary self- 
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assembly can form in either symmetric or asymmetric morphology depending upon the 
directional packing segments68–70. Hierarchical self-assembly is influenced by multiple 
factors such as polymer architects, intrinsic block functionality, and external triggers 
(Figure 1.5)71. In this dissertation, we demonstrate the controllable secondary self-
assembly for both asymmetrical and symmetrical structures. A multi-building block 
Janus nanostructure and a nanosatellite structure are examples for asymmetrical and 
symmetrical formations respectively. 
 
Asymmetrical Janus structures 
Janus, in terms of particles, has been named after the Roman God, who has two 
faces on the opposite direction. This term has been adopted to explain the 
nanoparticles that have two different properties on the opposite side of the particles 
including materials, surface ligands, and morphologies72. There are several approaches 
to develop Janus particles such as surface masking, co-jetting, crosslinking, and self-
assembly techniques73. However, we focus only on the self-assembly approach in this 
dissertation. Self-assembly of nanoparticles is able to generate asymmetricalstructures 
if the different building blocks have different favorable packing direction74. These 
building blocks will form the structure that keeps themselves the most stable.   
Asymmetrical structures provide different applications from conventional 
symmetrical structures. First, two different surfaces of the Janus can conjugate with bi-
ligands in an asymmetrical fashion resulting in bi-specific binding to two different types 
of cells. Another example is Janus motors, in which one side of the Janus particle can 
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react with a catalyst reagent creating a propellant and driving the particle forward in a 
uni-direction75. The concept of Janus motors has been recently introduced to a 
biomedical application for cargo delivery and permeability enhancer76,77. Nevertheless, 
the thorough investigations for possible clinical usage and long-term safety are still 
required
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1.4 Nanoparticles for vaccine delivery 
Vaccine definition by CDC refers to a product that boosts a person’s immune 
system to produce immunity to a specific disease and protect one from that particular 
disease. Vaccines have long been used for 215 years since it was first discovered by 
the farmer Benjamin Jesty and the physician Edward Jenner, who implemented 
attenuated pustules from cowpox and inoculated to people preventing them against 
smallpox. Since then the word vaccine and this technique have spread worldwide with 
on-going development78,79. Several decades ago, vaccines were mainly made from 
whole-cell pathogens, live attenuated pathogens, and inactivated pathogens.  However, 
these conventional types of vaccine have greatly safety concern. Later, subunit vaccine, 
DNA vaccines, and peptide vaccines were developed to improve the safety; however, 
these vaccines provide lower immunogenic response. As a consequence, an adjuvant 
may be required to help elicit better immune response (figure 1.6) 80.  Currently, vaccine 
products mostly contain both an antigen and adjuvant. Adjuvants are substances added 
into vaccine products in order to boost the immunogenicity of an antigen. Adjuvants can 
be ranging from the classical ones such as alum and Freund’s adjuvants to modern 
ones which engage the pathogen-associated molecular pattern (PAMPs) such as 
oligodeoxynucleotides (ODN)81,82.  The classical adjuvants are likely to stimulate 
inflammasome non-specifically, while modern adjuvants can specifically bind to pattern 
recognition receptors (PRR) such as STING, TLR 9 and NLR, which can subsequently 
elicit more effectively T helper cell response82.  
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 However, recombinant DNA antigens, soluble peptide antigens, and water-
soluble adjuvants are not effectively internalized by antigen presenting cells in vivo due 
to rapid degradation and diffusion regardless of their strong potency in vitro. This 
hampers the use of these molecules in clinical setting.  With the advent of 
nanotechnology, nanoparticles have been deployed to assist soluble antigen and 
adjuvant delivery to antigen presenting cells (APC) such as dendritic cells and 
macrophages by either passive or active ligand targeting methods.  
1.4.1 Passive and active delivery 
1.4.1 a) Passive vaccine delivery  
 
Passive delivery is mostly controlled by size of the nanocarriers. The 
nanoparticles with the size less than 200 nm can travel to lymph nodes directly and are 
internalized by APC in lymph nodes, while the nanoparticles with the size larger than 
500 nm are uptake by peripheral APC at the site of administration and then travel to the 
lymph nodes. The former provides the better adoptive immunity because first, less than 
5% of APC travel from the site of administration to lymph nodes and second, the 
antigens can directly interact with B cells through B cell receptors (BCR) and positively 
influence the antibody production81,83–85.  
1.4.1. b) Active vaccine delivery 
	
Likewise, other active targeting deliveries, vaccine can also specifically target to 
dendritic cells (DC). Some targeting ligands were used to deliver an antigen to DC such 
as CD-40, DEC-205, and gp 9686,87. However, to target DC, the choices of ligands used 
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depend upon specific DC subtypes. For example, DEC-205 expresses on the surface of 
CD8+ DC and presents the antigen in a context of both MHC-I and MHC-II, while 33D1 
expresses CD8-DC and presents the antigen on only MHC-II88. DC targeting is not only 
for antigen delivery, but also provides some specific signal that might polarize the DC in 
different manners. For instant, Targeting DC with asialoglycoprotein receptor induces 
DC to secrete IL-10 and polarize T cells into suppressor T cells88. Thus, targeting DC for 
appropriate immune response remains challenging. More deep investigations need to 
be conducted.  
Ex vivo techniques have also been used to activate DC outside the body and the 
cells are re-administered back to in vivo. This approach is so called “Dendritic cell 
vaccine”. This method readily primes DC to present the antigens to T cells and strongly 
boost the cytokines secretion from DC, which provides better T cell activation88. DC 
vaccine can also increase the positive NK cell responses and support the production of 
cytotoxic T lymphocytes (CTL) immunity resulting in tumor rejection. There are some 
on-going clinical trials of DC vaccine mostly are in phase I/II against melanoma. Overall 
toxicity reports are tolerable. Systemic side effects are rare and patients’ life quality 
seems to be preserved89. However, DC vaccines are considered as personalized 
therapy because DCs are generated and expanded from the patients to prevent 
rejection. There are some critical challenges to implement this technique including the 
standard procedures of the manufacturing, quality controls, consistency, routes of 
administration89. Moreover, it is less than 5% of ex vivo activated DC reaching the 
lymph nodes. This dampens the effect of activated DC leading to low immune response 
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and pre-condition may be required90. Nevertheless, the discovery of this technology laid 
the platform for future DC vaccine and move to the forefront of cancer immunotherapy.  
 
1.4.2 Factors influencing the nanoparticle engineering for vaccine delivery 
Nanoparticles play a crucial role in facilitating antigen and adjuvant delivery to 
APC. Numerous studies show that antigen and/or adjuvant-loaded nanocarriers elicit 
better immune responses, reduce off targets, reduce doses of antigens and adjuvant 
used, and protect antigens and adjuvants from degradation. However, there are several 
criteria contributing to a delivery system. Size, surface charges, morphology, elasticity, 
and antigen density on the surface of nanoparticles contribute to overall immune 
response and toxicity.  
1) Size: As mentioned in the earlier session, it has been well studied that nanoparticles 
with the size less than 200 nm can directly travel to lymph nodes, whereas the 
nanoparticles with the size larger than 500 nm required APC trafficking to lymph 
nodes due to the narrow lymph node capillary. However, the APC can squeeze 
themselves and penetrate the endothelial layer and traffic to the lymph nodes91,92. 
The optimal size for DC uptake is approximately 40 nm81. Microparticles are more 
favorable to be internalized by macrophages93. Although both DC and macrophages 
are considered as professional APC, delivering antigens to DC is more preferred 
because the antigen cross-presentation to T cells is more efficient in DC. 
Macrophages tend to degrade the antigen in lysosome after phagocytosis rather 
than to present it to MHC-I/II in endoplasmic reticulum94. 
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2) Surface charges:   similarly to other cells, cationic nanoparticles are uptake more 
efficiently in APC than anionic nanoparticles due to the interaction with negatively 
charged plasma membrane. However, the limitation of cationic nanoparticles is 
toxicity. The cationic nanoparticles can cause acute systemic toxicity and 
nonspecific systemic immune responses. Chen et al show that many types of 
cationic nanoparticles such as PEI, polylysine, cationic dextran and cationic gelatin 
can interact with TLR4 and induce the release of IL-1295. The charge effect is more 
complicated when the nanoparticles bound with plasma proteins, which impacts the 
cell uptake and biodistribution.  
3) Morphology:  The shapes of the nanoparticles affect not only the cellular uptake but 
also cytokine productions. The ability of cellular uptake relies on the angle of the 
nanoparticles that contacts to the cells. For asymmetrical nanoparticle such as 
nanorods, the cellular uptake is increasing if the transverse axis interacts with the 
cell membrane. Agarwal and his team discovered that nanodiscs have higher uptake 
in bone-marrow derived macrophages (BMDM) than nanorods96. Moreover, different 
morphologies of the nanoparticles influence different cytokine productions. Nanorods 
are likely to promote inflammasome-related cytokine release such as IL-1b and IL-
18, while nanospheres induce proinflammatory cytokine release such as TNF-a and 
IL-6. T cell polarization is also affected by the morphology of the nanocarriers. 
Nanospheres promote both Th1 and Th2 polarization against OVA antigen, whereas 
nanorods promote only Th2 polarization97.  
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4) Elasticity of nanoparticles: Nanoparticles with higher elasticity have higher  lymph 
node accumulation compared to the rigid nanoparticles with the same size. The 
nanoparticles with elasticity can squeeze themselves through the paracellular of the 
endothelial cells and travel to lymph nodes81. Moreover, elasticity of nanoparticle 
facilitates the antigens or targeted ligand conjugated on the surface of the 
nanoparticles bind to the cell surface receptor easier due to the binding flexibity98.   
5) Ligand density: Ligand or antigen density is a key factor to stimulate a proper 
immune response. DCs have to present a sufficient density of peptide-MHC complex 
on their surface in order to activate T cell response. T cells, in general, ignore the 
low density of the peptide-MHC complex99–101. This is important to design the 
nanoparticles mimicking APCs. Furthermore, the density of the antigenic peptides 
and their pattern on the surface of nanoparticles determines the interaction with the 
B cells. Non-repetitive self-antigens usually fail to elicit B cell response81. In order to 
bind the antigens with high affinity, B cell receptors need to be sufficiently engaged 
with the antigens. The highly repetitive structures can induce extensively cross-
linking of B cell receptors102. Surface antigen density also contributes to the ability of 
IgG to neutralize the whole antigen. The distance between the antigenic molecules 
should be approximately 10 nm so two identical arms of Fab of the IgG can form a 
strong bivalent bridge with the antigen102. Bandyopadhyay and co-workers show that 
different ligand densities on the surface of the nanoparticles induce different cytokine 
releases, which affects T cell response. Higher density of DEC-205, which targets 
DC, enhances the release of anti-inflammatory cytokines such as IL-10 via the 
cross-linking mechanism of the DEC-205 receptor103.  
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1.4.3 Nanoparticles as a vaccine platform 
Several nanoformulations have been explored for delivering antigenic peptides 
and adjuvants due to their ability to traffic to lymph nodes, prevent antigen and adjuvant 
degradation, elicit stronger immune response, and prolong the adjuvant release.  
I. Inorganic-based nanoparticles 
	
The most often inorganic-based nanoparticles used for vaccine delivery is gold 
nanoparticle (AuNP) due to the tunable surface and biocompatibility. As mentioned 
earlier that surface of AuNP readily reacts with thiol-based functional groups including 
cysteine on a peptide and thiol-modified oligo nucleotides. In general, the size of 
inorganic nanoparticle is well-controlled and can be as small as virus, which is easily 
uptake by DC104,105. PEG is usually used as a linker between AuNP and antigenic 
peptides, oiligo nucleotides, or adjuvants not only to increase the stability of the 
nanoparticles, but also to improve the flexibility of the ligands for receptor binding. The 
flexibility of the ligands is reported to be important for the ligands to bind with the 
pathogen recognition receptors (PRR) on the DC39.  
Another type of inorganic nanoparticles which has been intensively used for 
vaccine delivery is iron oxide nanoparticles (IONP) due to biodegradable and imaging 
property. IONP can be tracked without additional labelling process. IONP reduces T2 
relaxivity and darkens the tissues, where it accumulates, hence the biodistribution of 
IONP-based vaccine can be visualized under magnetic resonance imaging (MRI)106,107.  
II. Lipid-based nanoparticles 
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Liposomes are the most widely used lipid-based nanocarriers for the vaccine. 
The antigens and/or adjuvants can be loaded either inside the liposome or conjugated 
on the surface108–110. The latter provide better immune response due to the antigenic 
recognition and direct interaction with PRR on the APC. Antigens and adjuvants can be 
conjugated on the surface by modified functional groups of lipids in liposomes. The 
sizes of the liposomes are mostly in the range of 100-500 nm, which is larger than 
inorganic nanoparticles in general. Cationic liposomes have higher cellular uptake 
compare to anionic and neutral ones. Some types of lipid such as a combination of 
phosphatidylethanolamine with carboxylic compounds offer the pH-triggered release. 
This pH-sensitive liposome can release the antigens and adjuvants in acidic pH of 
lysosomes via protonation.  
Recently, synthetic high density lipoprotein (HDL) has been used to deliver the 
antigens and adjuvants. HDL can form nanodisc structures with diameter ca 10 nm, 
which is much smaller than conventional liposomes. This facilitates DC uptake and 
trafficking to lymph nodes resulting in great immune response111.  
III. Polymer-based nanoparticles 
	
Poly (lactic-co-glycolic acid) or PLGA polymer is one of the most widely used for 
vaccine delivery due to its biodegradability, high safety profile, and FDA approval. The 
advantages of PLGA particles over the liposomes are the ability to slowly release the 
antigens and cost-effectiveness. PLGA particles offer the slow release by bulk erosion 
mechanism. The release rate can be manipulated by the ratios between glycolic and 
lactic acid, and molecular weight of the polymer112. Antigens and adjuvants are mostly 
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loaded inside the particles, which provide better protection for the cargos against 
external degradation91. However, the trapped molecules, sometimes, cannot fully 
release resulting in low antigen processing. Size of PLGA particles could be nanoscale 
or microscale; nevertheless, nanoscopic PLGA particles are more suitable to use as a 
vaccine platform than microparticles due to higher DC uptake112.      
IV. Viral-like nanoparticles 
	
Viral-like nanoparticles (VLP) is basically a self-assembly viral capsid without 
infection or reproducibility due to the lack of genome. VLP is considered safer than live-
attenuated viral vaccine. VLP elicits very strong both innate and adaptive immune 
response mainly because of the self-antigenic property and high immune cell 
uptake113,114. Human papilloma virus (HPV) vaccine (Gardasil and Cervarix) approved 
by FDA in 2006 are examples of the VLP vaccine currently available in the market. 
These HPV vaccines are composed of L1 capsid protein mimicking the HPV structures, 
which prime the immune cells to recognize and produce antibody against the L1 capsid 
proteins. However, these vaccines are limited to use only prophylaxis against new 
infection of HPV115,116.  
 
 In summary, nanoparticles provide substantial advantages for vaccine delivery, 
solve the problems of traditional vaccines, and boost the clinical outcomes. There are 
several vaccine platforms that can be used. Each of them provides different 
physicochemical characters. Mostly, there is no single system perfect for all but the 
vaccines are generally designed based on the purpose of treatments. The 
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developments of vaccine platform are avidly on-going for several infection diseases and 
cancers. Further studies of long-term efficacy and safety are still required.  
  
1.5 Dissertation 
 Gold and iron oxide nanoparticles are selected to study in this dissertation 
because of their biocompatibility and biodegradability properties. Numerous studies 
prove their safety in vivo, which makes them more likely to get FDA approval as 
nanocomposites and for advancement to clinical trials. They also have useful intrinsic 
properties for multi modal theranostics. Moreover, the size of inorganic nanoparticles 
can be precisely controlled and most are smaller compared to lipid-based or polymer-
based nanoparticles.  
 This study also focuses on the secondary structures of the gold/iron oxide 
nanocomposites because the secondary structures usually exhibit enhanced properties 
of the primary building blocks such as cumulative or coupling effects.  Therefore, I have 
aimed at developing new secondary structures, both asymmetrical and symmetrical, 
and to explore their new properties. Asymmetrical secondary structures offer different 
intrinsic properties from symmetrical secondary structures such as anomalous Brownian 
motion, gradient photoabsorption, and uneven light scattering. These bring about novel 
applications, which the symmetrical structures fail to offer. 
 In addition to the synergistic or combinatorial intrinsic properties, the secondary 
structures also offer advantages for cargo delivery. The secondary structures provide a 
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larger surface area and different surface chemistry for different types of bio-conjugation, 
which make them easier to perform stepwise conjugations. In my study, I demonstrate 
an application of the secondary structure, nanosatellites, for vaccine delivery because 
they allow a method to control the antigen pattern and increase the antigen density. In 
contrast, the primary structures have limited surface area and are not suitable for 
designed antigen pattern. As mentioned earlier in this chapter, antigen density and 
patterns are crucial for immunogenic recognition. Low antigen density leads to poor 
immunogenic response.  
 
Dissertation outline  
This dissertation employs inorganic nanocomposites composed of gold and iron 
oxide nanoparticles to fabricate secondary structures, both asymmetrical and 
symmetrical, using different types of polymers.  
The second chapter focuses on the invention of a thermo-cleavable polymer, 
which was used for the asymmetrical multi-building block Janus nanostructure formation 
by seed-mediated self-assembly technique. The mechanism of the Janus formation was 
then investigated. This asymmetrical Janus can be used as a potent photothermal 
contrast agent due to strong coupling effect between nanoparticles. Moreover, the 
uneven photothermal absorption between gold and iron oxide nanoparticles in Janus 
creates the active rotational motive under the near-infrared (NIR) laser light, which 
makes the Janus damage cancer cells more effectively than symmetrical nanoparticles.  
25	
	
The third chapter reports on the use of a thermo-cleavable polymer for controlled 
release of the model drug, doxorubicin, triggered by the NIR laser light. Iron oxide 
nanoparticles are used as the photothermal contrast to convert NIR light to heat, which 
subsequently disrupts the thermo-cleavable polymer and releases doxorubicin from the 
thermo-cleavable micelles.  
The forth chapter investigates the development of a symmetrical nanocomposite 
structure composed of gold and iron oxide nanoparticles called nanosatellites. An iron 
oxide nanoparticle acts as a core for the attachment of gold satellites. We demonstrate 
the application of the nanosatellites as a SATVAC vaccine platform. The nanosatellites 
provide a larger surface area and very high density of E7/E6 antigenic peptide 
conjugation, which elicits strong specific CD8+ T cell against HPV+ (Human papilloma 
virus) head and neck cancer. Di-cyclic nucleotide cGAMP adjuvant was also loaded on 
the surface of the nanosatellites. The nanosatellite vaccine exhibits robust innate 
immune response by promoting the up-regulation of type I interferon genes, dendritic 
cells (DC) maturation, and tumor growth inhibition.  
The last chapter, chapter five, the conclusions of all work in this dissertation are 
drawn. Future perspectives and potential applications are highlighted and discussed. An 
appendix denoting the work regarding the use of gold and iron oxide nanocomposites 
for ionizing radiation also included in this dissertation.  
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Figure 1.1 Surface functionalization of SPION. From ref.9 
	
Figure 1.2. The diagram shows the excretion and elimination of AuNP 
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Figure 1.3. General nanoparticles that have photothermal effect after light irradiation at 
appropriate wavelength 
Figure 1.4. General scheme for self-assembly. (from ref 67)  
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Figure 1.6. Types of vaccines, immunogenicity, and safety (ref 80) 
	
	
	
	
	
	
	
	
	
	
	
	
  
Figure 1.5. Factors influence hierarchical structure formations (from ref 71). 
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CHAPTER 2 
MULTI-BUILDING BLOCK JANUS SYNTHESIZED BY SEED-MEDIATED SELF-
ASSEMBLY FOR ENHANCED PHOTOTHERMAL EFFECTS AND COLORED 
BROWNIAN MOTION IN AN OPTICAL TRAP 
2.1 Abstract  
The asymmetrical features and unique properties of multi-building block Janus 
nanostructures provide superior functions for biomedical applications. However, their 
production process is very challenging. This problem has hampered the progress of 
Janus nanostructure research and the exploration of their applications. In this study, we 
generated an asymmetrical multi-building block gold/iron oxide Janus nanostructure 
(JNS) to enhance photothermal effects and display colored Brownian motion in an 
optical trap. JNS are formed by seed-mediated self-assembly of nanoparticle-loaded 
thermo-cleavable micelles (NP-TCM), where the hydrophobic backbones of the polymer 
are disrupted at high temperatures, resulting in secondary self-assembly and structural 
rearrangement. The JNS significantly enhanced photothermal effects compared to their 
homogeneous counterpart after near infrared (NIR) light irradiation. The asymmetrical 
distribution of gold and iron oxide within JNS also generated uneven thermophoretic 
force to display active colored Brownian rotational motion in a single-beam gradient 
optical trap. These properties indicate that the asymmetrical JNS could be employed as 
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a strong photothermal therapy (PTT) mediator, and a fuel-free nanoscale Janus motor 
under NIR light 
2.2 Introduction 
Janus, anisotropic, or patchy particles have long been in an interest of various 
applications. Their asymmetrical structures make them appealing for diverse functions, 
such as surface-reducing agents, electronic devices, catalysts, molecular imaging, 
diagnostics, and drug delivery systems1–4. Recently, multi-building block Janus, 
composed of multiple nanoparticles arranged in an asymmetrical pattern in a single 
entity, have been used in imaging, theranostics, and cargo deliveries5–7. These complex 
Janus structures provide superior properties and have more effective responses to 
external stimuli compared to a single-domain Janus particle of the same size. The multi-
building block Janus benefits from the high surface-to-volume ratio8 and strong 
interaction among metal nanoparticle building blocks9. Despite the exceptional qualities 
of the multi-building block Janus particles, the approach and control process to produce 
these complex structures on a nano scale are very challenging10. They require a high 
degree of control to direct the aggregate process. Conventional approaches for Janus 
nanoparticle (JP) production, such as surface masking and phase separation, mostly 
yield single domain JPs on a micron scale, which have limited use for biomedical 
applications11–14. Those strategies are not suitable for fabricating nano-scale multi-
building block JPs. The most promising strategy for multi-building block JP formation on 
a nanometer scale is to employ bottom up self-assembly to control the location of 
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nanoparticle distribution in block copolymers.  Previous research has  suggested that 
many factors significantly contribute to the location of nanoparticles inside micelles, 
such as affinities between nanoparticle-coating ligands and polymeric micelles15, 
relative lengths of polymer and nanoparticle size16,17, lengths of surface coating of 
nanoparticles16, glass transition temperature of the polymer18, and solvent effects19,20. 
These significant discoveries allow researchers to control the location of nanoparticles 
and form complex structures such as nanowires, nanosheets, cylinders and vesicles 21. 
However, not much research has focused on utilizing controlled nanoparticle location 
and self-assembly to fabricate a nano-scale asymmetrical multi-building block Janus 
structure composed of two different inorganic nanoparticles.  
Gold (AuNP) and iron oxide (IONP) nanoparticles are the most intensively 
studied inorganic nanoparticles. They show good safety profiles, biocompatibility, 
biodegradability, and efficacy in cancer theranostics22,23. Most importantly, AuNPs and 
IONPs have different photothermal conversion efficiencies. The temperature created by 
AuNP and IONP are different. As a result, the gold/iron oxide JNS experiences a 
thermophoretic force that causes the particle to rotate. Jiang et al. has shown that a 
micron-sized gold/silica Janus can generate a spin motion under 1064 nm laser 
irradiation due to self-thermophoresis of the microparticles, which can be visualized 
under microscope24.  However, it is challenging to generate active motion in nano-sized 
Janus structures, and even more difficult to visualize that active rotational motion.  
While optical trapping of Janus Nanostructures (JNS) has been previously 
demonstrated, those experiments were not designed to detect the active 
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motion25.Therefore, we intend to create an active spin motion from a nanoscale Janus, 
and use a modified optical trapping technique to detect the unique motion. An 
asymmetrical Janus structure has the potential to generate active motion for electrical 
and biomedical applications24. 
In this article, we report a novel fabrication of multi-building block Janus 
structures composed of two different inorganic nanoparticles, AuNP and IONP, using 
thermo-cleavable amphiphilic diblock copolymer to control the nanoparticle distribution 
and self-assembly of nanoparticles loaded in the thermo-cleavable micelles. To the best 
of our knowledge, this is, for the first time, using thermo-cleavable polymer to form 
asymmetrical Janus structures. The thermo-cleavable amphiphilic diblock copolymer, in 
which the hydrophobic backbone could be cleaved apart at high temperatures via retro 
Diels-Alder reaction, provides an unstable condition at high temperatures, which 
encourages AuNPs and IONPs to self-assemble into multi-building block JNS by micelle 
collision and fusion.  We found that our JNS expressed strong photothermal efficiency 
after near infrared (NIR) light irradiation, much stronger than that of their homogeneous 
counterparts, due to the strong collective effect of their AuNPs. The NIR laser light 
irradiation also created a temperature imbalance between the two different sides of the 
JNS, which caused the particles to rotate, resulting in distinct frequencies of colored 
Brownian motion under an optical trap. These unique characteristic suggest that the 
Au/IONP JNS could potentially be employed as for both photothermal therapy and 
nanoscale Janus motors at the same time 26. This is highly significant for the future 
research in vivo, where the penetration of nanoparticles in a tumor mass is limited at 
only the shallow layers of the tumor around blood vessels. Our JNS can possibly 
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overcome this problem as they can eradicate the cancer cells near the blood vessels 
and also simultaneously penetrate to the deeper layers of the tumor mass by self-
propelled motor and mechanical sheer force27–29. 
 
2.3 Results and Discussion 
2.3.1 Thermo-cleavable polymer synthesis 
The JNS were fabricated via self-assembly of nanoparticles loaded into thermo-
cleavable polymeric micelles.  We first synthesized the thermo-cleavable hydrophobic 
backbone via Diels-Alder reaction at 70 °C30,31. Molecular weight of the hydrophobic 
backbone is 5,090 Da measured by GPC and then poly ethylene oxide (PEO) molecular 
weight 5,000 Da was added and reacted with the maleimide functional group of the 
hydrophobic backbone via Michael addition. The final amphiphilic diblock thermo-
cleavable polymer (Da-b-PEO) has the molecular weight of 9,800 Da characterized by 
GPC and 1H NMR (Figure 1a, S1, S2 and S3). This polymer acts not only as a key 
component to control hydrophobic interaction between nanoparticles and the polymer 
itself, but also mediates the micelle fusion. The cycloadducts in the hydrophobic 
backbones can be cleaved apart at or above 90 °C via retro Diels-Alder reaction32, as 
proven by 1H NMR (Figure 1b and c). The data suggest that 84% of the formed 
cycloadducts were cleaved after the polymer was treated at 100 °C for an hour (Figure 
1d). The retro Diels-Alder causes hydrophobic backbone shortening and hydrophobic-
hydrophilic imbalance, which critically affects the thermodynamic stability and triggers 
self-assembly of the thermo-cleavable micelles (TCM).  
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2.3.2 Multi-building block gold/iron oxide Janus nanostructure (JNS) formation 
Gold and iron oxide nanoparticles were used to generate Janus nanostructures (JNS). 
Oleic acid-capped iron oxide nanoparticles (15 nm) (IONPs) and dodecanethiol capped 
gold nanoparticles (5 nm) (AuNPs) were encapsulated separately in the polymer to 
make IONP-loaded thermo-cleavable micelles (FeTCM) and AuNP-loaded thermo-
cleavable micelles (AuTCM) respectively. Transmission electron microscopy (TEM) 
images clearly showed that nanoparticles aggregated at the center of the micelles’ 
hydrophobic domain (Figure 2a, 2b) due to strong interparticle Van Der Waals 
attractions. TEM data suggest that FeTCMs and AuTCMs have average core diameters 
of 39.6 nm and 56.6 nm respectively (Figure S4). The hydrodynamic diameters of these 
two micelles are 78.82 nm and 94.88 nm, which are larger than the core diameters 
measured by TEM because of the interaction between polymer and the aqueous media 
(Table S1). Next, the excess molar concentrations of AuTCM were mixed with FeTCM, 
subsequently mixed together with the free thermo-cleavable micelle (TCM) seeds. This 
was followed by heat treatment (94 °C) to generate asymmetrical Au/IONP JNS. The 
excess molar concentration of AuTCM was used to ensure that all FeTCMs were fused 
with AuTCMs. This completed solution was purified by a magnetic separator to remove 
the unreacted AuTCMs. The amount of AuNPs and IONPs in JNS could be controlled 
by the concentration ratios between AuTCMs and FeTCMs (Figure S5). Percent yield of 
JNS is 97.16% calculated from the feeding amount of Fe in FeTCM. Transmission 
electron microcopy (TEM) (Figure 2c, d, and S6a) and scanning transmission electron 
microscope high angle annular dark-field (STEM-HAADF) (Figure 2e, and S6b) images 
illustrate that AuNPs and IONPs are combined together in a new single entity with a 
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well-defined asymmetrical nanostructure.  The average core diameter of the JNS 
measured by TEM is 86.5 nm (Figure S4) and hydrodynamic diameter measured by 
dynamic light scattering (DLS) is 100.3 nm. It is important to note that JNS formed by 
the self-assembly approach have a relatively small size, compared to Janus particles 
made by other conventional methods, which mostly yield particles in micron-scale single 
domains33. We performed X-ray energy dispersive spectroscopy (XEDS) element 
mapping to confirm that the JNS are composed of multiple AuNPs and IONPs in an 
asymmetrical pattern (Figure 2f). The formed JNS are stable over a period of 6 months 
after being stored at 4 °C. Dynamic light scattering data indicate no large aggregation in 
the solution (Figure S7). To prove that the thermo-cleavable polymer is a critical factor 
in the formation of our JNS, we used Polystyrene-b-polyethylene oxide (PS-b-PEO, Mw 
10,300 Da) as a control for non-thermo-cleavable micelles (non-TCM) to encapsulate 15 
nm IONPs and 5 nm AuNPs separately. This polymer cannot trigger self-assembly to 
form JNS after adding PS-b-PEO seeds at high temperature. These two types of 
nanoparticle-loaded micelles remained separate (Figure S8). We further ruled out the 
possibility that different capping ligands of AuNPs and IONPs cause a non-specific 
asymmetrical structure inside of TCM in an independent manner of polymer properties 
and self-assembly process. First, we mixed AuNPs and IONPs together 
homogeneously, then loaded them into the thermo-cleavable polymer to form micelles. 
TEM, STEM-HAADF imaging, and XEDS element mapping show that no well-organized 
asymmetrical JNS formation occurred (Figure 2g, h, and i). Under these conditions, 
AuNPs and IONPs mixed together in micelles randomly, forming a homogeneous 
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gold/iron oxide micelle (GMC) without any specific pattern. These data suggest that the 
thermo-cleavable polymer is critical for the self-assembly and self-reorganization 
processes that form our asymmetrical JNS. 
 
2.3.3 Ball-like and patchy secondary nanostructure formation 
We further studied seed-mediated self-assembly by following similar procedures to 
those for JNS formation, but using only one species of metal nanoparticles, either iron 
oxide or gold, mixed with the TCM seeds. TEM images clearly show the self-assembly 
process forming iron oxide ball-like nanostructures (FeBL) with diameter ca. 74.1 nm 
(Figure 3a and S4). This transformed structure was also confirmed by STEM-HAADF 
(Figure 3b and c). The images and density profiles of FeBL (Figure 3d) clearly indicate 
that the electron density was higher at the edges and lower inside the cores because 
nanoparticles aligned at the interface between hydrophilic PEG and hydrophobic 
residues after self-assembly. Notably, the self-assembly and transformation of 
nanoparticle-loaded TCM occurs regardless of nanoparticle type. We observed that self-
assembly and transformation also took place with AuTCM. TEM and STEM-HAADF 
images clearly show gold patchy nanostructures (AuPS) (Figure 3e, f, and g). The 
density profile also confirmed an internal void volume of AuPS with a larger diameter 
than FeBL, 281.0 nm (Figure 3h). These data suggest that the self-assembly and self-
reorganization process has transformed cluster nanoparticle micelles into secondary 
nanostructures. It is important to note that we did not observe self-reorganization and 
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transformation using the IONP-loaded in PS-b-PEO micelles with the non thermo-
cleavable polymer (PS-b-PEO) seed (Figure S9).  
 
2.3.4 Seed-mediated self-assembly process  
We further investigated the mechanism of JNS and secondary structure formation. It is 
clear that self-assembly and transformation are driven by thermodynamic force. Luo and 
Eisenberg previously demonstrated that an increased amount of an aqueous phase in 
micelle system could induce thermodynamic instability, leading to micelle fusion. 
Smaller micelles fused together and formed larger micelles in order to mitigate their 
interfacial energy penalty34,35. Nevertheless, micelle fusion is quite unlikely in the case 
of nanoparticle-loaded micelles. The fusion of micelles is highly dependent on the 
polymer’s properties and the nanoparticle diameters36,37. These NP-TCMs are stable, 
because the hydrophobic nanoparticles have a strong hydrophobic interaction within the 
hydrophobic polymer backbone. They are very rigid and less flexible, which makes 
micelle fusion and self-assembly of these NP-TCMs unusual. The hydrophobic 
attraction between the polymer backbone itself and the nanoparticles needs to be 
diminished in order to create an unstable state and to initiate the self-assembly process 
for micelle fusion of these FeTCMs and AuTCMs. We examined the mechanism of 
nanoparticle self-assembly by using only one species of metal nanoparticles and the 
free TCM seeds to reduce complexity. A series of TEM images confirms that AuTCM 
fused together until they were stable, then underwent phase separation and structural 
rearrangement.  Samples for TEM were taken at the beginning of heat treatment (Figure 
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4a) and two hours after the heat treatment began (Figure 4b-e). When the mixture of 
NP-TCMs and free TCM seeds in aqueous media was exposed to the high temperature 
(94 °C), the hydrophobic backbones in all micelle species subsequently cleaved apart 
via retro Diels-Alder reaction, resulting in a reduction of the hydrophobic attraction 
between the backbone and nanoparticles. At this stage, NP-TCMs become unstable 
and relatively flexible. As a consequence, these unstable NP-TCMs fused with free 
TCM seeds in the aqueous media. While one NP-TCM collides with the seed, a second 
NP-TCM can also fuse with the same seed from the opposite side (Figure 4f). The free 
TCM not only acts as a seed to mediate the self-assembly, but also enhances a 
depletion force between two NP-TCMs38,39. This leads to structural transformation and 
self-assembly, forming the JNS. If only one species of NP-TCM (either AuTCMs or 
FeTCMs) is mixed with free TCM seeds in the system, ball-like or patchy nanostructures 
will be formed instead of JNS. Although the self-assembly process is challenging to 
control, we were able to regulate JNS formation by varying the ratio between AuNPs 
and IONPs. In contrast, the system without free TCM seeds failed to transform into 
secondary nanostructures at a high temperature. It was observed that the hydrophobic 
nanoparticles were released into the aqueous media, where they precipitated (Figure 
S10). Without free TCM seeds, there is neither a template for NP-TCMs to anchor onto 
nor a depletant to attract NP-TCMs; consequently, the fusion process is not possible.   
The hydrophobic chain’s changes in length under high temperature conditions 
are critical for JNS formation via the self-assembly process. It has been reported that 
the relation between lengths of polymeric micelles and nanoparticle diameters is a 
significant factor for controlling the location of nanoparticles inside micelles16,17. In 
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general, the energy penalty increases with the increasing ratio between nanoparticle 
size and the coil dimension of the polymer. Since the nanoparticles’ radius of gyration is 
larger than the polymer’s radius of gyration after backbone cleavage, the nanoparticles 
are expelled from the matrix, and large-scale phase separation occurs40–42.  
 
2.3.5 Janus nanostructure enhances photothermal effect 
We further explored how our multi-building block Janus nanostructures interact with 
photothermal effect. Intriguingly, Au/IONP JNS significantly enhance temperatures 
when undergoing 885 nm NIR laser light irradiation at low laser power, 0.45W, with low 
concentrations of iron (40 µg/ml) and gold (170 µg/ml). Upon 10 minutes of NIR light 
irradiation, JNS gradually increased the temperature by 20.9 °C from the initial 
temperature in the cell culture media, while other controls, such as their homogeneous 
gold-iron oxide micelle counterparts (GMC), gold cluster micelles (AuTCM), iron oxide 
cluster micelles (FeTCM), a solution mixture of gold micelle and iron oxide cluster 
micelles, and cell culture media alone, increased only 15.0°C, 12.7°C, 7.3°C, 13.4°C, 
and 6.1°C from the initial temperature respectively (Figure 5a). Concentrations of gold 
and/or iron in all samples were fixed to the same or close to their concentration in the 
JNS. In addition, we further tested the enhanced photothermal effect on cancer cell. We 
monitored cell viability using an Alamar Blue assay when triple negative breast cancer 
cells (SUM159 cells) were treated with JNS under 885 nm NIR laser light. The high 
temperature created by the JNS resulted in lower cell viability compared to other 
treatments and the media control group. The cell viability of the group treated with JNS 
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under NIR laser light irradiation was 62.76%, while treatment using only the JNS, 
without NIR laser light irradiation, displayed no toxicity, with cell viability of 92.74% 
(Figure 5b).  
In order to induce cell death by photothermal therapy (PTT), the temperature 
must be higher than 41°C to unfold proteins and trigger cell death signaling43,44. 
Therefore, good photothermal contrast agents with high photo-conversion efficiency are 
necessary. These agents must be able to significantly increase the temperature of the 
surrounding environment under low NIR laser power 45,46. This is very important for ideal 
in vivo PTT, since low laser power has a minimal effect on surrounding normal tissues 
but effectively kills the cancer cells. It is noteworthy that the surface of JNS are covered 
by hydrophilic poly ethylene oxide (PEO) polymer. Though the hydrophobic backbone 
cleavage, the PEO remains intact. This makes JNS become stealthy and prevents 
protein absorption on the surface of JNS resulting in the reduction of phagocytosis by 
macrophages in vivo. Notably, our JNS demonstrate high photothermal efficiency at low 
laser power compared to their homogeneous counterparts. JNS clearly demonstrate 
overall higher absorption from 400 -900 nm (Figure S11). JNS may have “collective 
effects” by presence of multiple AuNPs in close proximity for higher PTT as described in 
literature47. Specifically, there are two mechanisms of interactions between AuNPs for 
the heating process: (1) accumulative effect of AuNP confined in JNS. The 
accumulative effect in AuNPs has been reported by Gorotov, et al (Nanoscale Res Lett, 
2006) resulting in the strong temperature enhancement48. This effect stems from the 
addition of heat fluxes of multiple AuNPs. Our JNS show absorption at lmax 1.61-fold 
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stronger than the gold-iron oxide homogeneous micelles counterparts (GMC) at the 
same concentration of Au and Fe. (2). The Coulomb effect is generated from the 
interaction among AuNPs in the JNS, which is also supported by literature reported by 
Zhang et al (Optic express, 2012)49. As a result, we observed a red shift from 504 nm to 
520 nm of JNS compared to GMC. The insertion of IONPs between AuNPs in GMC 
hinders the accumulative and the Coulomb effect of AuNPs. Therefore, GMC could not 
fully take advantage of the collective effect. These data suggest that the structural 
arrangement of nanoparticles plays a crucial role in photothermal effect of secondary 
structures.  
 
2.3.6 Janus nanostructures display colored Brownian motions under a single-
beam gradient optical trap 
Since our JNS’s structure is asymmetrical, with AuNPs on one side and IONPs the 
other, the two sides have different photothermal efficiencies as well22,23. The absorption 
of laser light by AuNPs and IONPs on the surface of the JNS creates an uneven 
temperature gradient. Therefore, the JNS experiences a thermophoretic force that 
causes the structure to rotate (Figure 6a). To validate this behavior and quantitate the 
rotation frequency, we employed an optical trap to monitor individual JNS for this active 
rotational motion at the focus of a NIR laser (λ = 830 nm). Incorporating back-focal-
plane interferometry (BFPI), this technique permits ultra-sensitive tracking and 
characterization of trapped sub-micron particles as recently applied to HIV-1 virions in 
culture media50. 
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 Power spectra from individually trapped particles are analyzed such that the laser 
alone is used as a baseline control (Figure 6b). Our data reveals that optically trapped 
JNS particles (N = 209) show a distinct peak at 0.5-3 kHz in their power spectra (Figure 
6c and d).  The presence of these peaks, i.e., apparent ‘colors’ in the thermal noise51, is 
in sharp contrast to the power spectra displayed by homogeneous polystyrene or silica 
nanoparticles when they were trapped under identical conditions52.  As a consequence, 
a typical Lorentzian fitting for these power spectra yielded bad fits, as indicated by the 
systematic deviations between the power spectra and the best fitted curves overlaid on 
the spectra.  As a matter of fact, these peaks are absent in all symmetric nanostructure 
controls including AuTCMs (N = 50) (Figure 6e) and FeTCMs (N = 75) (Figure 6f), 
respectively.  For these power spectra, the Lorentzian fitting provides an adequate 
description for the data over the entire frequency range that we have investigated (1- 30 
kHz).  Because these power spectra were recorded in the plane that is perpendicular to 
the laser beam axis (z-axis in Figure 6a), the presence of the peaks along both x- and y-
axis in this plane indicate that a population of JNS displays periodic rotational motions in 
the focal plane at a frequency between 0.5-3 kHz, which deviate from the typical 
Brownian motions, but consistent with the rotation of these particles with a major 
frequency between 0.5-3 kHz as driven by the local temperature gradient.  The colors of 
thermal noise in Brownian motions has been demonstrated previously for microscopic 
particles under strong trapping conditions53, which results from the correlated motions 
between a trapped particle and the surrounding solvent molecules54, or the so-called 
hydrodynamic memory effects.  The apparent colors in thermal noise that we observed 
here for the JNS particles must have a different origin.  First of all, these JNS are more 
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than tenfold smaller in diameter than microspheres used by Franosch et al53.  Particles 
of this size are very weakly trapped, as we showed previously50,52, and as a result, the 
effect of hydrodynamic memory is small.  The absence of these peaks in the symmetric 
particles we used as a control further supports this notion, and argues that it is the 
asymmetry within the JNS particles that gives rise to this phenomenon.  
While optical trapping of JNS has been previously demonstrated, those experiments 
were not designed to detect active motion25. Our observation, however, is supported by 
work from Jiang et al. examining self-thermophoresis of gold/silica Janus microparticles 
under 1064 nm laser irradiation24. It is worth noting that these asymmetrical JNS 
nanoparticles are more challenging to trap than symmetrical nanoparticles, due to the 
active spin motion. Although a portion of the current JNS sample exhibited a peak in the 
power spectra, the data are reproducible over multiple experiments.  Moreover, the 
frequency for this periodic motion is also reasonable for a particle of this size in a single-
beam gradient optical trap55.  Previous studies using polystyrene and gold nanoparticles 
subjected to circularly polarized light were able to achieve speeds up to 6 Hz and 
several kHz, respectively, the latter at a laser power of <50 mW and λ = 830 nm 56,57. 
Furthermore, at these rotation speeds corresponding to high thermophoretic forces, it 
was predicted that the ability to optically trap JNS becomes strongly inhibited, leading to 
particle escape58. This is a common occurrence during current trapping experiments, 
which suggests that a larger population of JNS may actually exhibit active rotational 
motion than what we were able to stably trap and measure here. 
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2.4 Conclusions 
We have generated an asymmetrical multi-building block Janus nanostructure (JNS) by 
employing a novel self-assembly approach that utilizes a thermo-cleavable polymer to 
control the location and self-assembly of nanoparticles.  The data suggest that the 
asymmetrical JNS enhance photothermal effect and provide uneven thermophoretic 
force under NIR light, which generates active colored Brownian spin motion. These 
properties of the asymmetrical JNS could be used as both a strong photothermal 
mediator and a fuel-free nanoscale Janus motor under NIR light, which provides 
superior functions in the future compared to particles that have only either photothermal 
properties or rotational motion alone. JNS can simultaneously induce cancer cells death 
by increasing local temperature and potentially penetrate deeper in a tumor mass by the 
active rotational motion. These two properties make our JNS unique and possible to use 
in the future for cell manipulations, tissue penetration enhancement, and cargo 
deliveries59–61.  
2.5 Materials and methods  
I. Synthesis of difurfuryl adipate (DFA): Difurfuryl adipate was synthesized using 
the previously published method62. Briefly, 5.5 mmol adipoyl chloride was added 
dropwise to 11 mmol furfuryl alcohol with a few drops of triethanolamine (TEA) in 
dichloromethane. The reaction was carried out at 0 °C for 3 hours under nitrogen 
atmosphere. The product was purified by silica gel column chromatography eluted with 
petroleum ether and ethyl acetate (2:1). The final product was brown viscous liquid. The 
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chemical structure was confirmed by 1H NMR spectroscopy (Varian 400 MHz) in 
dichloromethane (DCM)-d4 and tetrachloro ethane (TCE)-d2.  
Synthesis of cleavable hydrophobic backbone polymer, Diels-Alder polymer 
(DA): The DA polymer was synthesized from difufuryl adipate (DFA) and bismaleimido 
diphenyl methane (BMD) monomers following previous literature63,64. An equimolar of 
DFA and BMD was mixed in TCE and the reaction was carried out at 70 °C for 7 days. 
The viscous yellow liquid was precipitated by excess petroleum ether and pale yellow 
powder was obtained. The powder was dried out under vacuum conditions.  The final 
product was characterized by 1HNMR spectroscopy in TCE-d2. Molecular weight of DA 
was measured by gel permeation chromatography (GPC).  
Cycloadduct conversion: In order to determine the percentage of cycloadduct 
conversion, DFA and BMD were reacted at 70 °C for 48 hours to induce Diel-Alder 
reaction. Retro Diels-Alder occurred at 100 °C and lead to the cycloadduct cleavage. 
The percentage of cycloadduct conversion was calculated from the area under the 
peaks appearing in 1H NMR at 5.32 ppm and 7.43 ppm respectively. They indicated 
cycloadducts in the hydrophobic backbone and furan rings in the starting material 
respectively. 
% Conversion = {AUC at 5.32ppm / [AUC at 5.32 ppm + AUC at 7.43 ppm]} x 100 
Synthesis of thermo-cleavable polymer (DA-b-PEO) via Michael addition: The 
excess molar concentration of thiol-methoxy polyethylene oxide, molecular weight 5,000 
Da (SH-mPEO), was added into the solution of DA polymer (1.5:1 molar ratio) in DCM 
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with a few drops of TEA. The solution was kept under stirring for one night and the 
product was precipitated into petroleum ether. The polymer structure was confirmed by 
1H NMR spectroscopy. Molecular weight was determined by GPC. 
Synthesis of IONPs: 15 nm IONPs were synthesized using a previously reported 
method65. Briefly, a mixture of 0.890 g FeO(OH),19.8 g oleic acid and 25.0 g 1-
octadecene in a three-neck flask were heated under stirring to 200 °C under N2. 30 
minutes later the temperature was set at 220 °C for 1 h, then the temperature was 
increased gradually to 310 °C (20 °C/5 minutes) and kept at this temperature for 1 h. 
The solution became black when the temperature was increased to 320 °C and kept at 
this temperature for 1 h. After the reaction was completed, the reaction mixture was 
cooled and the nanocrystals were precipitated by adding chloroform and acetone. 
Au/IONP Janus nanostructure (JNS) formation: FeTCM (2.7 nM), AuTCM (0.2 
µM), and DA-b-PEO (10.0 µM) were mixed together at room temperature. The solution 
was subsequently heated at 94 °C for 3 hours in a dry bath. The obtained JNS were 
centrifuged twice to remove free polymer seeds. The JNS solution was kept at 4 °C in 
the magnet separator (EasySep, USA) for one night to remove unreacted AuTCM.  
Synthesis of FeBL and AuPS secondary nanostructures: To form iron oxide ball-
like nanostructures (FeBL), FeTCM (0.54 nM) were homogeneously mixed with TCM 
seeds (0.2 µM) at room temperature. The formation of the ball-like structures was 
carried out at 95 °C for 2 hours in a dry bath. Then the solution was centrifuged to 
remove free TCM seeds and the pallets of ball-like nanostructures were redispersed in 
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Milli Q water. To form gold patchy nanostructures (AuPS), AuTCM (0.4 µM) was mixed 
with free TCM seeds (10.0 µM). The solution was heated at 94 °C for 3 hours in a heat 
block and purified by centrifugation. The final products were stored at 4 °C. 
Synthesis of homogeneous Au/IONP micelles (GMC): Oleic acid coated-IONPs 
(1mg) and dodecanethiol AuNPs (1 mg) were dissolved together in THF and 
subsequently added into 20 mg of DA-b-PEO solution in THF under stirring. The 
resulting solution was slowly dropped into water under vigorous agitation. The product 
was purified twice by weight-separated centrifugation. 
Characterization of nanoparticle: NP-loaded TCM, secondary structures, and 
JNS samples for TEM imaging were prepared by the solvent evaporation method. 
Briefly, the solution (5 µL) of each sample were dropped onto carbon-coated copper 
TEM grids and allowed to dry overnight. TEM images were acquired on a transmission 
electron microscope (TEM, Phillips CM-100, 60 kV). Scanning transmission electron 
microscopy (STEM) and X-ray energy dispersive spectroscopy (XEDS) were performed 
using Jeol JEM-2010F, operating at 200 kV with a double tilt holder. Images and size 
distributions were analyzed by ImageJ software from NIH and Gatan digital micrograph 
software. Hydrodynamic diameters were measured by using Malvern Zeta Sizer Nano 
S-90. Concentrations of Fe and Au were quantified by Inductively Coupled Plasma - 
Optical Emission Spectroscopy (ICP-OES) (Perkin-Elmer Optima 2000 DV). The 
samples were digested in aqua regia overnight before measurement. Percent yield of 
JNS was calculated by the equation shown below.  
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% yield of JNS = [Amount of Fe in JNS x 100]/ Amount of Fe in FeTCM 
Photothermal effect and cell viability assay in triple negative breast cancer cells 
(SUM-159): The cells were cultured in a 5% CO2 environment in F12 media (Invitrogen, 
Carlsbad, CA) supplemented with 5% fetal bovine serum (Fisher Scientific, Pittsburgh, 
PA), 1% antibiotic– antimycotic (Invitrogen, Carlsbad, CA), 5 µg/ml insulin (Sigma-
Aldrich, St Louis, MO), 1 µg/ml hydrocortisone (Sigma-Aldrich, St Louis, MO), and 4 
µg/ml gentamicin (Invitrogen, Carlsbad, CA). 3x103cells were seeded in 96 well-plates 
overnight. The cells were incubated with JNS (0.17 mg/ml of gold and 0.04 mg/ml of 
iron), AuTCM (0.17 mg/ml of gold), FeTCM (0.04 mg/ml of iron), GMC (0.17 mg/ml of 
gold and 0.03 mg/ml of iron), solution mixture of AuTCM (0.17 mg/ml of gold) and 
FeTCM (0.04 mg/ml of iron), or cell culture media alone for 2 hours. The cells were 
irradiated using a NIR laser (885 nm, 0.45 W, spot size 5x8 mm2, MDL-III- 885, OPTO 
Engine LLC, Midvale, UT) for 10 minutes. The temperature of the solutions was 
measured using a thermal camera (FLIR, Boston, MA). Nanoparticles were removed 
immediately after PTT and the cells were incubated overnight. Alamar blue (BIO-RAD, 
Raleigh, NC) was added to each well and incubated for 4 hours before fluorescent cell 
viability measurement at Excitation: 540 nm and Emission: 590nm.   
Optical trapping of JNS: A custom-built optical tweezers instrument incorporating 
a tapered amplifier diode laser at 830 nm (SYS-420-830-1000, Sacher LaserTechnik 
LLC, Germany) was used for trapping AuTCM, FeTCM, and JNS samples. Briefly, the 
trapping laser was focused to a diffraction-limited spot using a 60X water-immersion 
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objective (Nikon, Melville, NY) with a numerical aperture of 1.2. The laser power was 
130.8 mW at focus throughout the experiments, which were conducted at 20 ± 0.2 °C. 
Samples were diluted 10-fold in distilled water and separately injected into a microfluidic 
chamber of our construction. The optical trap is initially stationary, allowing individual, 
diffusing nanoparticles to be passively captured. Brownian motion of trapped particles 
was recorded with BFPI at 62.5 kHz for 10 s for the two axes that are perpendicular to 
the z-axis, i.e., the laser beam axis along the direction of beam propagation. This scan 
was repeated four times.  Fitting of the corresponding power spectra in MATLAB (The 
Mathworks, Natick, MA) was done as previously described50.  If the particle still 
remained in the optical trap after all scans were completed, it was released and a new 
particle was trapped after sufficient time had elapsed. 
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Figure 2.1. a) A synthesis scheme of DA-b-PEO amphiphilic diblock thermo-cleavable copolymer. An 
equimolar of DFA and BMD was mixed in tetrachloro ethane and the reaction was carried out at 70 °C for 
7 days. The molecular weight of the polymer was 5,090 Da. Then SH-mPEG was conjugated with the 
maleimide terminus of the hydrophobic backbone via Michael addition and yielded the final product with 
the molecular weight of 9,800 Da. b) A cartoon picture representing the thermo-cleavable polymer and 
the hydrophobic backbone cleavage after high temperature exposure. c) 1H NMR of the hydrophobic 
backbone at different time points and temperatures: freshly prepared (top), 48 hours after 70 °C heat 
treatment (middle), and 1 hour after 100 °C heat treatment. It clearly shows that the cycloadducts peak at 
3.09 and 5.32 ppm increase after polymerization via Diels-Alder reaction at 70 °C for 48 hours. However, 
these peaks disappear after the temperature increases to 100 °C for an hour. This indicates the 
cycloadduct disruption via retro Diels-Alder. d) 84% of the cycloadducts were cleaved after being treated 
at 100 °C for an hour. The data suggest that the backbone cleavage is very efficient after one hour of high 
temperature exposure. 
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Figure 2.2. TEM images of Janus Nanostructures (JNS). a) The TEM images of the original FeTCM and 
b) AuTCM before heat treatment. c) A TEM image of multi-building block Au/IONP JNS after self-
assembly process. d) A high magnification TEM image and a cartoon picture show an asymmetrical 
structure of JNS. e) A STEM-HADDF image of JNS and f) XEDS element maps of JNS confirm an 
asymmetrical pattern of JNS. g) TEM, h) STEM, and i) XEDS images of homogeneous dodecenethiol-
coated AuNPs and oleic-coated IONPs loaded in TCM show a random pattern of Au/IONP mixture in 
micelles (GMC) 
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Figure 2.3. The TEM images of secondary structures.  a) and e) represent TEM images of FeBL and 
AuPS after self-assembly of FeTCM and AuTCM respectively. b) and f) demonstrate STEM-HADDF 
images of FeBL and AuPS at low magnifications. c) and g) are STEM-HADDF images of FeBL and AuPS 
at high magnifications with a color heat map. d) and h) show density profiles of FeBL and AuPS, implying 
that nanoparticles aligning at the polymer interface rather than inside the core. 
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Figure 2.4. TEM images and scheme of self-assembly process. a) TEM image of AuTCM at high 
magnification. The sample was taken at the beginning of heat treatment. b) - d) Series of TEM images 
showing multiple AuTCMs fusion process. e) TEM image demonstrating internal phase separation and 
structural rearrangement to form secondary structures. Scale bars from (a-e) are 100 nm. f) Schematic 
diagram demonstrates the transformation mechanism from cluster micelles to multi-building block Janus 
or ball-like nanostructures. First, a FeTCM collides with free TCM seed. Simultaneously, another AuTCM 
can also collide with the same seed from the opposite direction and subsequently fuse together, resulting 
in self-reorganization to form JNS. If only one kind of NP-TCMs is used, ball-like or patchy structures will 
be formed instead of JNS. 
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Figure 2.5. JNS enhances photothermal effect. a) Graph shows photothermal effect of different types of 
nanoparticles. JNS significantly enhances the temperature after NIR laser light irradiation at 885 nm for 
10 minutes comparing to other structures. The asterisk shows significant difference, P-value < 0.05. b) 
Percentage of SUM-159 cell viability with and without photothermal treatment in different types of 
nanoparticles. The asterisks show P-value < 0.05.  
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Figure 2.6. JNS displays colored Brownian motions in a single-beam gradient optical trap.  a) A 
hypothetical cartoon to illustrate the local temperature imbalance around a single JNS particle, which 
drives the rotation of the particle at the focal plane.  b) Power spectra for laser-only collected along x- and 
y-axis.  c-d) Representative power spectra for JNS particles displaying rotational motion in the optical 
trap.  The best Lorentzian fits for each spectrum are overlaid, resulting in reduced c2values of 1.31 (red in 
c), 1.33 (purple in c), 1.21 (red in d) and 1.20 (purple in d), respectively.  e-f) Representative power 
spectra for AuTCMs and FeTCMs in the optical trap, respectively.  The best Lorentzian fits for each 
spectrum are overlaid, resulting in reduced c2 values of 1.11 (red in e), 1.11 (purple in e), 1.10 (red in f) 
and 1.11 (purple in f), respectively.  For panels b-f, the power spectra along x-axis are shown in cyan 
while the power spectra along y-axis are shown in blue.  The fits for spectra along x-axis are shown in red 
while the fits for spectra along y-axis are shown in purple.  The xy plane is the focal plane that is 
perpendicular to beam axis z. 
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2.8  Supporting information 
 
 
Figure 2.S1. A synthesis scheme of DFA monomer. DFA was synthesized from furfuryl alcohol and 
adipoyl chloride in DCM with a few drops of TEA under nitrogen atmosphere at 0°C for 3 hours. DFA was 
characterized by 1H NMR (400 MHz, TCE-d2) δ 7.43 (d, J = 2.0 Hz, 2H), δ 6.41 (d, J = 2.8Hz, 2H), δ 6.37 
(dd, J1 = 3.6Hz, J2 = 2.0Hz, 2H), 5.04 (s, 4H), 2.34 (p, J1 = 7.2 Hz, J2 = 3.2Hz, 4H), 1.63 (t, J = 3.4 Hz, 
4H). 
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Figure 2.S2. 1H NMR of hydrophobic backbone Diel-Alder polymer (a), bismaleimido diphenyl methane 
(BMD) (b), and difurfuryl adipate (DFA) (c). BMD and DFA covalently form cycloadducts as shown in 1H 
NMR at δ 7.30 (d, J = 8 Hz, 4H), δ 7.19 (d, J = 8 Hz, 4H), δ 6.55 (d, J = 6.4 Hz, 2H), δ 6.43 (d, J = 5.6 Hz, 
2H), δ 5.32 (s, 2H), δ 4.91 (d, J = 13.2 Hz, 2H), δ 4.47 (d, J = 13.2 Hz, 2H), δ 4.04 (s, 2H), δ 3.09 (d, J = 
5.6 Hz, 2H), δ 3.02 (d, J = 6.4 Hz, 2H), δ 2.34 (m, 4H), δ 1.63 (m, 4H). The asterisk (*) indicates a solvent 
peak.  
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Figure 2.S3. Core diameters and size distributions of JNS, AuTCM, AuPS, FeTCM and FeBL measured 
by TEM and analyzing by Image J. 
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Table 2.S1. The table shows hydrodynamic diameters and polydispersesity index of TCM seed, FeTCM, 
AuTCM, and JNS. Each sample was measure in triplicate by using Malvern Zeta sizer with disposable 
cuvettes. The core diameters of micelles measured by DLS are larger than the diameter of micelles 
measured by TEM because of the interaction between the media and the polymer coating nanoparticles.     
	
	
	
	
	
	
	
	
	
	
	
 Hydrodynamic Diameter (nm) Polydispersity index (PDI) 
TCM 93.82 0.35 
FeTCM 78.82 0.22 
AuTCM 94.88 0.24 
JNS 100.30 0.12 
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Figure 2.S4. TEM images show the different number of AuNP and IONP and structural differences of 
JNS formed from different ratios of AuTCM and FeTCM. The percentage of AuNP in AuTCM was varied 
as indicated in the Figure ures. 1% and 5% of AuTCM yielded uncompleted JNS and FeBL were found in 
the product after purification. While 20% AuNP in AuTCM show over excessive AuNP that are unreacted 
to FeTCM and free TCM resulting in releasing single AuNPs and cause precipitation. 10% AuNP in 
AuTCM represent the optimal JNS nanostructures as there is neither unreacted AuNP nor FeBL 
appearing in TEM images.  
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Figure 2.S5. a) and b) represent a TEM and STEM-HADDF image of JNS showing that multiple AuNP 
and IONP are combined together as a single entity regardless of their orientation under the TEM and 
STEM. Darker tiny dots under TEM image and brighter spots under STEM image indicates AuNPs. The 
big grey spheres under TEM image and dark sphere under STEM represent IONPs.  
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Figure 2.S6. TEM images of the mixture of 5 nm AuNPs encapsulated in non-TCM (PS-b-PEO) and 15 
nm IONPs loaded in non-TCM before (a) and after (b) 3 hours of high temperature treatment with free 
non-TCM seeds. The data suggest that there was no JNS formation. These two types of NP-TCMs 
remained separated in the solution. Scale bars are 100 nm.  
	 	
74	
	
	
	
	
Figure 2.S7. TEM images of FeTCMs before (a) and after (b) heat trigger. Morphological transformation 
of FeTCM is clearly observed under TEM. The cluster FeTCMs can undergo self-assembly and form 
FeBL. (c) and (d) show TEM images of nonFeTCMs before and after heat trigger respectively. No 
structural transformation was observed.  
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Figure 2.S8. (a)Top panel shows that IONPs were released from the micelles and precipitated in the 
aqueous media. The amount of precipitation is inversely proportional to the amount of free TCM seeds. 
(b)The bottom chart shows percentage of iron precipitation released from the micelles at different weight 
ratios of the TCM seed with the fixing amount of IONPs (1mg). 
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CHAPTER 3 
THERMO-CLEAVABLE POLYMERIC MICELLES FOR NIR-TRIGGERED DRUG AND 
NANOPARTICLE DELIVERY 
	
3.1 Abstract 
A novel thermo-cleavable polymer, difurfuryl adipate-bismaleimido diphenyl methane-b-
polyethylene oxide (DA-b-PEO), was developed for NIR-triggered drug release and 
nanoparticle delivery. The hydrophobic polymer backbone, difurfuryl adipate-
bismaleimido diphenyl methane (DA), is dissociated after being exposed to high 
temperature (80°C) or near-infrared light (NIR) via retro Diels-Alder reaction. The 
polymer was characterized by 1H nuclear magnetic resonance (1H NMR) and gel 
permeation chromatography (GPC). Iron oxides nanoparticles (IONPs) and Doxorubicin 
(Dox) were simultaneously encapsulated in thermos-cleavable polymeric micelles. 
IONPs are used as a photothermal mediator and Dox is used as a model drug. IONP 
can convert from NIR light to heat, which induces polymer backbone cleavage that 
releases both IONPs and Dox from micelles. The amount of Dox release was 
determined by UV-visible spectrophotometer. We also observed and confirmed by 
transmission electron microscopy (TEM) the transformation process from clustered 
IONP micelles to single-dispersed IONP micelles. The transformation occurs 
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simultaneously with the release of the payload. After the polymer backbone cleavage, 
the cleaved polymer interacts with the released IONPs and transforms them into single-
dispersed IONP micelles. These IONP-Dox thermo-cleavable micelles can be used for 
non-invasive and light-triggering control drug release. 
3.2 Introduction 
Polymeric micelles have long been studied for decades yet still gain a lot of interest for 
drug delivery for a number of reasons. They improve not only physicochemical 
properties of the loaded-drug but also control drug release over a period of time at a 
particular area1.  Several kinds of polymer have been investigated such as PLGA and 
PCL because of their biodegradability. However, the ability to control over the drug 
release triggered by external stimuli needs to be improved. Triggered-responsive 
materials have recently attracted a great deal of attention from researchers2,3. These 
materials better control over drug release at specific targets to maximize therapeutic 
outcomes and minimize adverse drug reactions from non-specific release. One of the 
most common methods to trigger drug release is to use temperature4. Most traditional 
thermal sensitive polymers can undergo the structural change between hydrophilic and 
hydrophobic parts of the polymer. Some polymers have a lower critical solution 
temperature (LCST) such as Poly (N-isopropylacrylamide, P-NIPAAM). They can 
undergo phase changes when heated above LCST leading to structural shrinkage and 
squeezing out a small molecule drug. Whereas polymers that possess an upper critical 
solution temperature (UCST) can swell and become more hydrophilic when the 
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temperature is above their UCST2,5,6,7,8. However, the polymer backbones of these 
traditional thermal sensitive polymers fail to cleave resulting in incapability of releasing 
nanoparticles loaded inside the micelles. The nanoparticles remain in big clusters, ≥ 100 
nm in size and may obstruct deep tumor penetration9,10,11. To overcome high interstitial 
pressure and dense collagen matrix in tumor, nanoparticles with the size smaller than 
50 nm are necessary12. As a consequence, cleavable polymeric backbone could be a 
promising approach to release these nanoparticles. One of the most well-known 
reversible chemical reactions between furan and maleimide called Diels-Alder reaction 
and retro Diels-Alder (rDA), was discovered in year 1928 in Germany by Professor Otto 
Diels and his student, Kurt Alder. This discovery results in receipt of the Nobel Prize in 
Chemistry in 195013. In year 1994, Kuramoto et al synthesized a hydrophobic polymer 
by using this reaction. They used difurfuryl adipate (DFA) for the furan source and 
bismaleimido-diphenyl-methane (BMD) for the maleimide source14. After that DA 
reaction has been intensive studied by using different structures of furan and maleimide 
molecules15. However, Diels-Alder reaction has limited application because it requires a 
relatively high temperature to induce the reversible reaction. McElhanon et al, 2004 
synthesized an easily removed surfactant by using 2-N-dodecyl hydrophobic furan and 
N-(4-hydroxyphynyl) hydrophilic maleimide16. This surfactant was proved useful as 
removable templates for the construction of microporous materials. Yamashita, 2011 
made use of the maleimide-modified polyethylene glycol (Mw 20,000) to conjugate with 
furfuryl disulfide-gold nanorods. The high temperature induces rDA resulting in the 
release of polyethylene glycol from gold nanorod surface17. Nevertheless, to our 
knowledge, there is no any Diels-Alder amphiphilic block copolymer previously 
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synthesized before. Our group modifies the method previously published by Kuramoto 
to make the hydrophobic polymer backbone (DA-polymer) and we subsequently have 
another additional step to conjugate thiol polyethylene glycol (SH-mPEG, Mw 5,000) by 
using Michael addition to the hydrophobic DA polymer. After the conjugation, the 
thermocleavable amphiphilic block copolymer was obtained and can be self-assembly 
as thermocleavable micelles.  This amphiphilic block copolymer has different properties 
from the hydrophobic Diels-Alder polymer synthesized by Kuramoto and more suitable 
for biomedical applications.  
Iron oxide nanoparticles (IONPs) have long been used for magnetic resonance 
imaging (MRI), hyperthermia, and photothermal therapy (PTT)18,19 because of their 
unique properties and safety. IONPs can reduce T2 relaxation providing contrast images 
for the tumor areas and also generate high temperature under alternating magnetic field 
or NIR light treatment20. With these properties, IONPs could be used as diagnostic and 
PTT agents for cancer treatment. 
We report herein the Diels-Alder amphiphilic block copolymer synthesis and its 
applications for controlled drug and nanoparticle release. With this novel amphiphilic 
block copolymer, we are able to transform the cluster nanoparticles encapsulated in the 
micelles to single-dispersed nanoparticles and control drug release simultaneously. The 
single-dispersed nanoparticles benefit deep tumor penetration. In this report, iron oxide 
nanoparticles (IONPs) are used as a photothermal mediator to convert near-infrared 
light (NIR) to heat21,19. The heat subsequently breaks apart the polymer backbone via 
retro Diels-Alder reaction (rDA)22,23 resulting in the release of both the nanoparticles and 
a small molecule drug. Doxorubicin (Dox) is encapsulated into the thermo-cleavable 
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micelles together with IONPs. Dox was chosen as a model drug because it has been 
used in clinic for cancer treatment. During the process of transformation, Dox can also 
be released out of the micelles. This demonstrates that our thermo-cleavable polymeric 
micelles can generate both single-dispersed nanoparticles and control drug release at 
the same time leading to deeper tumor penetration and better therapeutic outcomes.  
3.3 Results 
3.3.1 Doxorubicin loaded in DA-b-PEO thermo-cleavable micelles. 
 The thermo-cleavable polymer was synthesis as previously reported in the 
chapter one. The molecular weight of the copolymer 8,900 Da determined by GPC. Dox 
and IONP (5 and 15 nm) were loaded into the polymeric micelles by a solvent 
evaporation method (figure 3.1). Dox was first deprotonated by trimethylamine (TEA) in 
DMSO. The color of the solution immediately changed. Oleic acid coated IONP (15 nm) 
were also co-loaded into the thermo-cleavable micelles (TCM) at the same time. The 
hydrophobic Dox and IONP were successfully loaded into the micelles. Loading 
efficiencies of Dox and IONP 15 nm are 1.7% and 3.3% respectively. Encapsulation 
efficiencies of Dox and IONP 15 nm are 16.7% and 32.7% respectively (Table 3.1). 
Hydrodynamic diameter of Dox-IO-TCM is 123.3 nm with polydispersity in (PDI) 0.518 
measured by a dynamic light scattering method, and zeta potential 0.228 mV. 
Transmission electron microscope (TEM) images confirm the DOX-IO-TCM formation 
(figure 3.2). The diameter from TEM is in general smaller than the diameter measured 
by DLS because DLS will be affected by the interaction between the media and the 
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particle coated by polymer. The size of Dox-IO-TCM is very promising for passive 
particle delivery due to the leaky blood vessels in tumor called enhanced permeability 
and retention effect (EPR). EPR allows the nanoparticles with size less than 200 nm to 
accumulate in the tumor. The Polystyrene polyethylene oxide diblock copolymer (PS-b-
PEO) with molecular weight 10.3 KDa was used as a non-thermo- cleavable control 
micelles. Both Dox and IONP (15nm) were encapsulated in the non-thermo-cleavable 
micelles (non-TCM) by using the similar method.  
3.3.2. Photothermal induction of DOX-IO-TCM and Dox release after near infrared 
(NIR) laser irradiation/ high temperature treatment 
 We first proved that DOX-IO-TCM have a great photothermal efficiency. Dox 
encapsulation and polymer coating both TCM and non-TCM do not negatively impact 
the photothermal ability of IONP. 10 minutes after NIR laser irradiation, the surface 
temperature of the Dox-IO-TCM and Dox-IO-non-TCM in aqueous solution is 82.3 °C 
and 87.4 °C respectively, while the temperature of phosphate buffer saline (PBS) 
control is only 36.5 °C. The initial temperature of all samples is 29 °C. The temperatures 
significantly increase in both Dox-IO-TCM and Dox-IO-non-TCM compared to PBS 
control group (figure 3.3). We further investigated the Dox release from the micelles. 
After 24 minutes of NIR laser irradiation at 2.5 watts, the amount of Dox release from 
Dox-IO-TCM is 4-fold higher than the amount of Dox release from the TCM without NIR 
laser irradiation. Moreover, the amount of Dox release from the non-TCM remains no 
different between with and without NIR laser irradiation, which is 4-fold lower than Dox 
released from the TCM (figure 3.4a). The data suggest that Dox released from the non-
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TCM and TCM without NIR laser irradiation results from premature release, which is 
very common in micelles because hydrophobic molecule can sometimes non-
specifically attach to the outer layer of the micelles. This phenomenon has been 
observed in many kinds of polymeric particles and micelles24–26. We also used a dry 
bath as a direct heat source to trigger the TCM cleavage and Dox release. The result of 
the Dox-IO-TCM and Dox-IO-non-TCM exposed to the direct heat at different time 
points demonstrates that after Dox-IO-TCM was heat at 80 °C, 60 minutes, the amount 
of Dox release into the media is 3-fold higher than Dox released from non-TCM (figure 
3.4b). The amount of Dox released from the non-TCM was consistent, 3-5%, and did 
not increase significantly over the time 0 to 60 minutes at 80 °C. In contrast, the amount 
of Dox released from TCM was slightly increasing from 3.79 to 7.09% after 10 and 30 
minutes after the heat treatment. After the TCM were continued exposing to the heat at 
80 °C, we observed the burst of the TCM and hydrophobic precipitants in the media. 
The amount of Dox released at 60 minutes of the heat treatment is 15.2%. It was 
noticed that Dox form solid aggregates with IONP in the media, whichwas difficult to 
extract the Dox for UV measurement; although, we used chloroform to extract the Dox 
from the solid complex. This observation implied that the amount of Dox release would 
be higher than our measurement. It is interesting that time to induce the TCM burst 
release is significantly shorter than using the dry bath. This observation suggests that 
NIR laser irradiation is more efficient to raise up the temperature and induce the retro 
Diel-Alders reaction of the hydrophobic backbone of the polymer. This is due to the fact 
that IONP can generate very high temperature on their surface and the heat 
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subsequently dissipate to the hydrophobic backbones of the polymer, which stay 
adjacent from the IONP. Therefore, the temperature at the surface of IONP is expected 
to be a lot higher than the temperature we observed in the media27. In contrast, the dry 
bath heats up the whole media and is not specific to the IONP so the temperatures at 
the surface of IONP and the media are not significantly different.  
3.3.3. NIR laser irradiation induces the release of IONP from DOX-IO-TCM 
 We investigated whether NIR laser irradiation and high temperature treatment 
can induce the release of IONP from the TCM. The Dox-IO-TCM and Dox-IO-non-TCM 
were placed into a dry bath at 80 °C and 37 °C for 2 hours. There was no aggregate 
formation from both Dox-IO-TCM and Dox-IO-non-TCM after 2 hours of 37 °C 
treatment. This indicates that both micelles were stable at 37 °C and no IONP released 
to the aqueous media. However, after 2 hours of 80 °C treatment of Dox-IO-TCM, IONP 
and DOX aggregates were clearly formed. The Dox-IO-non-TCM still remained the 
same and there was no aggregate formed (figure 3.5a). We also observed the similar 
phenomenon when the NIR laser was used to triggered IONP release (figure 3.5b). 
TEM images confirmed the release of IONP from the TCM. The IONP became single 
nanoparticles after 2 hours of 80 °C treatment or 24 minutes after NIR laser irradiation. 
These data imply that the high temperature or NIR laser irradiation triggers the thermo-
cleavable polymer disruption and subsequently the burst of the TCM resulting in the 
release of IONP at the same time with Dox. In contrast, the IONP loaded in non-TCM 
remained in micelle clusters after the high temperature or NIR trigger as shown in the 
TEM images (figure 3.6). The released IONP from the Dox-IO-TCM became single 
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suspended nanoparticles because the cleaved thermo-cleavable polymer, which still 
had the short hydrophobic part and hydrophilic PEO, can react with the released 
hydrophobic IONP making some of the single hydrophobic IONP suspended in the 
media. However, some IONP that were not coated with the cleaved polymer formed big 
aggregates and precipitated from the solution. The amount of the released IONP over 
exceeded the amount of the polymer in the system; therefore, only some of the released 
IONP could react with the cleaved polymer. This is the reason we observed both solid 
aggregates and single IONP dispersion in the solution after high temperature or NIR 
laser treatment.  
 The release of single IONP may facilitate the tumor penetration of the 
nanoparticles as the single IONP can penetrate deeper in the tumor mass. Huo and 
coworker demonstrated that gold nanoparticles with 50 nm diameters can penetrate 
deeper in a tumor spheroid model and accumulated more effectively in a tumor 
xenograft mouse model. While the gold nanoparticles with 100 nm diameter stayed 
around blood vessels10.  Therefore, the released IONP from the micelle cluster may be 
able to penetrate deeper in the tumor mass resulting in better in vivo photothermal 
therapy.  
3.4 Conclusion 
 
The DA-b-PEO could be used as a thermo-cleavable polymer for triggered-drug and 
nanoparticle release simultaneously after triggering by NIR laser irradiation or high 
temperature treatment. The IONP convert the NIR laser light into heat and the heat 
subsequently cleaves apart the hydrophobic backbone of the thermo-cleavable polymer 
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by inducing the retro Diel-Alders reaction leading to the burst of the micelles. Dox and 
IONP release from the micelles at the same time. This could be used as a double 
therapy. The photothermal effect can induce cell apoptosis due to high temperature and 
Dox is a chemotherapeutic agent, which has been used in clinical practice. Therefore, 
our discovery could be useful for cancer therapy in the future. However, more detailed 
studies are required such as in a mouse xenograft model.  
3.5 Materials and methods 
 
Materials: furfuryl alcohol (98%), triethanolamine (TEA,99%), dioxane (99.5%, extra 
dry), and1,1,2,2 tetrachloro ethane (TCE,98.5%) were purchased from Acros Organics. 
Petroleum ether (certified ACS grade), and dichloromehane (certified ACS grade) were 
purchased from Fisher Scientific. Ethyl acetate (anhydrous, 99.8%), tetrahydrofuran 
(THF, anhydrous 99.8%), adipoyl chloride, bismaleimido diphynyl methane (BMD), and 
dimethyl sulfoxide (DMSO, 99.5%) were purchased from Sigma-Aldrich. Thiol methoxy 
polyethylene oxide 5KDa was purchased from NanoCS. Doxorubicin HCl (99.5%) was 
purchased from Polymed therapeutics. Polystyrene-b-polyethylene oxide (Ps-b-PEO), 
Mw 10,300 Da used for the control micelles was purchased from Polymer Source.  
 
Synthesis of IONPs: 15nm IONPs were synthesized by using previously reported in the 
literature19. Briefly, a mixture of 0.890 g FeO(OH),19.8 g oleic acid and 25.0 g 1-
octadecene in a three-neck flask was heated under stirring to 200°C under N2, 30 
minutes later the temperature was set at 220°C for 1 h, then the temperature was 
increased gradually to 310°C (20°C/5 minutes) and kept at this temperature for 1 h. The 
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solution became black when the temperature was increased to 320°C and kept at this 
temperature for 1 h. After the reaction was completed, the reaction mixture was cooled 
and the nanocrystals were precipitated by adding chloroform and acetone. 
 
Synthesis of difurfuryl adipate (DFA): difurfuryl adipate was synthesized by using the 
previously published method by Kuramoto, 199414. Briefly, adipoyl chloride was added 
dropwise to furfuryl alcohol in cold dioxane. The reaction continues at 0°C for 3 hours. 
The product was purified by column chromatography using petroleum ether and ethyl 
acetate (2:1) as a mobile phase. The final product was viscous brown liquid and the 
structure was confirmed by using H1NMR spectroscopy. 
 
Synthesis of cleavable hydrophobic backbone polymer, Diels-Alder polymer (DA): the 
DA polymer was synthesized from difufuryl adipate (DFA) and bismaleimido diphenyl 
methane (BMD) monomer as reported by Gandini, 200928. An equimolar of DFA and 
BMD was mix in TCE and the reaction continued at 70°C for 9 days. The final product 
was precipitated in petroleum ether and characterized by using H1NMR spectroscopy.  
 
Synthesis thermo-cleavable polymer (DA-b-PEO) via Michael addition: the excess molar 
concentration of thiol-methoxy polyethylene oxide, molecular weight 5,000 Da (SH-
mPEO), was added into the solution of DA polymer in DCM with a few drops of TEA. 
The reaction continued overnight and the product was precipitated in petroleum ether. 
The polymer structure was confirmed by using H1NMR spectroscopy and molecular 
weight was determined by using GPC.  
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IONPs-loaded and Dox-IONPs loaded micelles formation: for IONPs-loaded micelles, 
4mg of 15nm IONPs were mixed with 40mg of DA-b-PEO in 4ml THF. Then the solution 
was transferred dropwise into 40ml water under vigorous agitation. The solution was 
open to the air overnight to evaporate THF. IONP-loaded micelles were purified by 
centrifugation twice to get rid of free micelles. For Dox-IONPs loaded micelles, Dox.HCl 
was deprotonated overnight with TEA (1:2 molar ratio) in DMSO to get the hydrophobic 
Dox29. Then 4mg of hydrophobic Dox was mixed with IONPs and DA-b-PEO 
respectively in THF. The similar method with making IONP-loaded micelles and 
purification were used for formulating Dox-IONP loaded micelles. Polystyrene-b-
polyethylene oxide (PS-b-PEO) was used for making non-thermocleavable control 
micelles. Encapsulation and loading efficiency of IONPs and Dox were determined by 
UV spectrophotometry.  
 
Photothermal effect determination: 0.2mg/ml 15nm IONPs were used for generation of 
the photothermal effect from both thermo-cleavable micelles and the control micelles. 
200ul of each sample were put on 96-well plate and were exposed to the NIR laser 
885nm, 2.5W/cm2with 5x8mm spot size. Phosphate buffer saline was used as a control. 
The temperature was measured by thermal camera.  
 
Dox release determination: After the samples were either heated at 80°C or exposed to 
NIR light, the released Dox was extracted by using 200ul of chloroform. Subsequently, 
the chloroform layer was taken and evaporated overnight. Dox powder was 
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reconstituted in DMSO and the amount of released Dox was measured by UV 
spectroscopy.  
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Figure 3.1. A The schematic picture demonstrates the DOX-IO-TCM formation. The hydrophobic 
part of the thermo-cleavable polymer entraps hydrophobic molecules such as Dox and IONPs, The 
hydrophilic one assembly as shells, which helps increase solubility and prolongs blood circulation 
time in the body. Both IONPs and Dox are spontaneously encapsulated into the hydrophobic core of 
the micelles. Dox- IONP loaded non thermo-cleavable micelles (Dox-IO non TCM) was produced 
with the similar method to Dox-IONP loaded TCM; however, PS-b-PEO was used instead of DA-b-
PEO.  
 
Table 3.1. The table shows encapsulation and loading efficiency of DOX-IO-TCM and DOX-IO-NON-
TCM.   
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Figure 3.2. TEM images of DOX-IO-TCM at low magnification and high magnification confirms 
that Dox and IONP were successfully encapsulated in the micelles.   
 
Figure 3.3. a) and b) the images show the final temperatures of the Dox-IO-TCM and Dox-IO-non-
TCM in PBS solution. The temperatures were measured by a thermal camera. c) The graph shows 
the temperature increases of Dox-IO-TCM, Dox-IO-non-TCM, and PBS control. The initial 
temperatures of all samples are 29 °C. 10 minutes after NIR laser irradiation 2.5W , the 
temperatures of Dox-IO-TCM and Doc-IO-non-TCM increase to 82.3 °C and 87.4 °C respectively, 
while the final temperature of PBS control increases to only 36.5 °C. The data suggest that the 
polymer used for micelle encapsulation and Dox do not affect the photothermal efficiency of IONP. 
The experiments were done in triplicates.  
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Figure 3.4 a) The chart demonstrates the percent of Dox released from Dox-IO-TCM and the 
control micelles, Dox-IO-non-TCM with and without 24 minutes of NIR laser trigger (2.5 W), 885 
nm. NIR laser can trigger the Dox release from TCM and Dox was released 4-fold higher than 
NIR laser trigger for the non-TCM and 3.43 fold higher than TCM without laser trigger. There is 
no difference in non-TCM between with and without NIR laser irradiation. b) The percent of 
cumulative Dox release at different time points after the TCM and non-TCM were exposed to the 
high temperature at 80 °C. Dox- from TCM has a burst release at one hour after being treated at 
80 °C, while non-TCM still have low Dox release.  
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Figure 3.5 External triggers induce micelles dissociation for controlled drug release application. Both 
Dox-IONP loaded TCM and non-TCM are stable at 37°C. There is no aggregate formed after 2 hours 
of 37°C exposure (a, left). In contrast, after 2 hours of 80°C treatment, Dox-IONP loaded TCM are 
ruptured and release the payload as the big aggregates are obviously formed. The aggregates are 
the hydrophobic residues of the thermo-cleavable polymer, Dox, and unencapsulated IONPs. There 
is no aggregates formed from non-TCM; even thought, they are exposed to the same temperature 
with the TCM (a, right). Both Dox-IONP loaded TCM and non-TCM are also exposed to NIR laser for 
24 minutes to examine the NIR-induced drug release (b). After NIR laser trigger, Dox-IONP loaded 
TCM form big aggregates similar to the heat treatment at 80°C, while there is no significant change in 
Dox-IONP loaded non-TCM. This indicates the non-TCM are insensitive to the high temperature and 
NIR laser triggers as well as incapability of releasing the payload. It is explained that the TCM 
release Dox and IONPs by temperature-induced Diels-Alder reaction resulting in the cleavage of the 
cycloadduct in the hydrophobic backbone of the polymer. Moreover, this also indicates that both high 
temperature and NIR light can be used as external stimuli for controlled drug release from our TCM. 
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Figure 3.6. TEM image of the Dox-IONPs loaded thermo-cleavable micelles before (A), after 
temperature trigger at 80°C (B), and NIR laser irradiation (C). Figure A shows that IONPs form micelle-
like clusters. In contrast, after 80°C or NIR laser exposure, Dox-IONPs loaded thermo-cleavable 
micelles loss the micelle-like structure and become single-dispersed IONPs as shown in figure B and 
C. (D) shows Dox-IONPs loaded non-thermocleavable micelles, control micelles. However, non-TCM 
remain their micelle-like structure after 80°C (E) or NIR laser exposure (F). This confirms that our TCM 
can be cleaved and reattach back to make the single-dispersed IONP micelles.  
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CHAPTER 4 
ENGINEERING HPV ANTIGENIC-PEPTIDES AND ADJUVANT CONJUGATED 
NANOSATELLITE VACCINE FOR HEAD AND NECK CANCER TREATMENT 
 
4.1 Abstract 
Head and neck squamous cell carcinoma (HNSCC) is one of the most common cancers 
worldwide. Previously, the main cause of HNSCC had been smoking and alcohol 
consumption but in recent years there has been a shift towards initiation by HPV 
infection in the last decade due to changes in sexual behavior. While there are 
vaccinations for cervical HPV cancers, there are no specific treatments for the HPV-
positive HNSCC. Current treatment regimens are identical for HPV-positive and HPV-
negative HNSCC. Although anti-PD-L1 antibody was approved for this indication, the 
clinical response rate of HNSCC to immunotherapy is generally below 20%. A strategy 
for treating hypoimmunogenic tumors is lacking. Thus, new strategies are needed for 
treating hypoimmunogenic tumors. We propose to boost anti-tumor immunity against 
the HPV-positive HNSCC using an inorganic nanoparticle-based vaccine to deliver E7 
and E6 HPV antigenic peptides and cGAMP, a small molecular adjuvant, to professional 
antigen presenting cells. The nanosatellite particles enhance the peptide density, 
promote the cellular uptake, and prevent rapid in vivo clearance of the antigenic peptide 
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and adjuvant. We found that our nanosatellite vaccine induces IFN-I production and 
promotes tumor antigen-specific CD8+ T cells that led to reduced tumor burden.  
 
4.2  Introduction 
Head and neck cancer is a type of malignant tumors that develop in or around head 
and neck areas such as the throat, larynx, oral cavity, nasal cavity, and oropharyngeal 
area1. 90% of the head and neck cancer have been considered as squamous cell 
carcinomas2. Head and neck squamous cell carcinoma (HNSCC) is one of the most 
common cancers worldwide and in the United States 5% of all cancer patients have 
been diagnosed as HNSCC. There are 11.9% new case arising globally in year 2012 
with 4.5% death rate in all cancers2–4. Classic risk factors of HNSCC development are 
tobacco and alcohol consumption; however, the trend of pathogenesis of HNSCC is 
shifting from the classic risk factor to human papiloma virus (HPV) infection due to 
altered sexual behavior5. HPV has become a major underlining cause of HNSCC in 
men, accounting for 2/3 of the HNSCC patients. The current incident rate of HPV+ 
HNSCC is highest among young white male population. Interestingly, according to 
Center for Disease Control and Prevention (CDC), the incident rate of HPV16/18 
positive HNSCC in men is as high as the incident rate of HPV 16/18 positive cervical 
cancer in women. Moreover, it is predicted that, by year 2020, the incident rate of HPV-
positive HNSCC will surpass the incident rate of HPV-positive cervical cancer6,7. 
Regardless of the underlining causes of HNSCC, the same standard of care are used, 
such as surgery, ionizing radiation, chemotherapy, or adjuvant therapy8. 
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Immunotherapy has been recently entered clinical used for HNSCC treatment. Food 
and Drug Administration (FDA) has approved anti-PD-L1 antibody used for HNSCC 
treatments in United State in 2016 after clinical trials demonstrated the better prognosis 
and higher survival rate than the standard therapy without the anti-PD-L1 combination9–
11. Nevertheless, only 20% of HNSCC patients respond to the immunotherapy 
treatment9–12. This implies that only the checkpoint blockade against T cell exhaustion is 
not sufficient for HNSCC treatments. HNSCC is considered a hypoimmunogenic tumor, 
which is more resistant to effector immune cells and often fails to elicit tumor antigen 
(TA)-specific cytotoxic T lymphocytes (CTLs). Unfortunately, current HPV vaccines used 
for HPV16/18 cervical cancer prophylaxis have been neither approved for HPV16/18 
HNSCC nor cervical cancer treatment by FDA. Therefore, the need of HPV-positive 
HNSCC treatment is still unmet. One of the most promising strategies to treat this 
disease is to boost hosts’ anti-tumor immunity and to generate a T cell-inflamed tumor 
microenvironment. Type I interferon (IFN-I) has been known to be a key player of innate 
immunity to elicit antigen presenting cells (APC) and maintain an effective anti-tumor 
immune response13.  
There are several approaches to promote type I IFN against tumors. Cyclic 
dinucleotides (CDNs) such as cyclic GMP-AMP (cGAMP) have been known to activate 
the adaptor protein stimulator of interferon genes (STING), which promotes IFN-I 
induction14–16. It is promising to utilize the cGAMP as a potent adjuvant in HNSCC 
vaccine to promote T cell inflamed tumor microenvironments. CDNs have demonstrated 
profound tumor regression in melanoma after intratumoral injection to 
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immunocompetent mice17,18. However, intratumoral delivery is not favorable in clinical 
applications. The fact that cGAMP is a hydrophilic small molecule, which has rapid 
clearance from the body before they reach the targets, hampers it from being used in 
clinics. Nanotechnology can offer solution to solve this problem. Similar to the cGAMP 
adjuvant, HPV antigenic peptides also require an effective delivery system to reach the 
targets for antigen cross-presentation to T cells in lymph nodes. E6 and E7 protein have 
been well reported as HPV oncoproteins, which impair the function of tumor suppressor 
proteins such as p53 and pRB19,20. These two oncoproteins have become great targets 
of the vaccine to boost specific T cell activity against HPV-positive HNSCC because 
they are absent in normal host cells. E6 and E7 epitopes are soluble peptides, which 
have rapid diffusion and degradation in physiological conditions. Therefore, they are not 
suitable to use alone as a synthetic peptide vaccine. A peptide conjugation with 
nanoparticles can help minimize the clearance and degradation of the soluble peptides. 
Importantly, both adjuvant and the antigenic peptides need to be able to escape from 
the lysosome and go to cytosol in order to stimulate downstream cascades for type I 
IFN production and loaded onto major histocompatibity complex (MHC) class I21,22.   
One of the alternatives is to deliver tumor antigenic peptides and adjuvants to 
stimulate APC resulting in T cell cross-priming. To effectively deliver the antigenic 
peptides and adjuvants to APC in vivo, nanocarriers must be properly designed. Size, 
shape and surface area are critical factors for engineering vaccine carriers23. It has 
been well-known that nanoparticles deliver antigens more effectively than microparticles 
due to the limitation of APC uptake24. Previous reports show that dendritic cells prefer to 
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uptake nanoparticles, which have around the same size with virus (< 200 nm) and the 
optimal size for cell uptake is around 50 nm 25–27. Moreover, nanocarriers at this size 
can travel to lymph nodes directly or take advantage of APC-facilitated trafficking to 
lymph nodes, where APC can cross-present the antigen to T cells and consequently 
activate specific immune response against the tumors28,29. Ligand density on the 
nanoparticles is also another important aspect needed to be considered for vaccine 
design. Higher ligand density conjugated on the surface of nanoparticles elicits stronger 
immune response and cytokine release30,31. These aspects prompt us to engineer 
nanosatellite particles used for delivering the E6/E7 antigenic peptides and cGAMP 
adjuvant to the APC to promote type I IFN production and activate specific T cell 
immune response against HPV-positive HNSCC.  
The nanosatellite particles are composed of two types of inorganic materials with 
iron oxide nanoparticles as a core surrounded by small gold nanoparticle satellites32. 
This core-satellites system enhances overall surface area of the particles for the 
peptides conjugation resulting in the higher local peptide density. The externally 
conjugated peptides on the surface of the particles promote B cell activation better 
compared to the antigen trapped inside the polymeric or liposomal nanoparticles. 
Moreover, nanosatellite particles are biodegradable and biocompatible. The iron oxide 
core can be degraded in the lysosome of splenic and hepatic macrophages to become 
ferric and ferrous, which are endogenous substances and then recycled in a form of 
hemoglobin33,34. While, gold nanoparticles with the diameter less than 6 nm regardless 
of surface charge can be excreted out of the body through the renal clearance35,36. 
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These physicochemical properties offer advantages for the vaccine carriers. We 
consequently engineered the nanosatellite vaccine carrying E6/E7 oncogenic peptides 
and a small molecule adjuvant, cGAMP and investigated the efficacy of the 
nanosatellite vaccine to promote innate immunity and specific T cell activation for HPV-
positive HNSCC treatments both in vitro and in vivo.  
4.3 Results and discussion 
4.3.1 Nanoparticle synthesis and characterizations 
 Nanosatellite particles were synthesized as previous reported37. Briefly, iron 
oxide nanoparticles coated with poly (g- methacryloxypropyl trimethoxysilane) -b- poly 
(ethylene oxide) polymer (MPS-b-PEO) were homogeneously mixed with gold sulfide 
nanoparticles (AuS) at different ratios. Average diameter of AuS nanoparticles is ca 2-4 
nm measured by transmission electron microscopy (TEM). Silane functional group of 
the MPS-b-PEO polymer strongly anchors on the surface of iron oxide nanoparticle, 
while thiol functional group on the polymer can covalently bind to the surface of gold 
nanoparticles. The number of gold nanoparticles on an iron oxide core is adjustable by 
molar ratios of gold and iron oxide nanoparticles (figure 4.1a-f). The number of AuNP is 
proportionally increasing when the higher volume of AuNP solution was added (figure 
4.1 g-i). However, the higher ratios of AuNP/IONP core compromise the stability of the 
nanosatellite particle overall because the excessive amount of AuNP causes the 
crosslinking between nanosatellite particles, resulting in precipitation. Our data suggest 
that the ratio of Fe 1 mg: AuNP 3 ml provides the decent numbers of AuNP/IONP core, 
which are approximately 10 AuNP/IONP. From a mathematic calculation, the distance 
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between each AuNP is 10 nm. The solution remains stable over a month at 4°C (figure 
4.2 a and b).  
 We further conjugate modified E7 and E6 oncogenic peptides on the surface of 
the nanosatellite particles via maleimide-thiol chemistry called Michael addition (scheme 
1). Acetylthio-PEG5K-Maleimide was used to conjugate with thiol-modified E7 R9F or 
E7 Q19D peptide. The formed thioether bonds are stable and non-reversible, which is 
suitable for peptide delivery. The acetyl-PEG-E7 was deacetylated to yield free thiol 
functional groups before further conjugation with the nanosatellite particles. The E7 
conjugated nanosatellites were purified by a magnet separator to eliminate the unbound 
peptide and PEG linkers. The supernatant was collected and used for determining E7 
conjugation efficiency. We performed similar work for the modified E6 peptide. The 
conjugation efficiency is 92% measured by Lavapep (figure 4.2 c). There are 
approximately 1,000 peptide/Au satellite and 10,000 peptide/whole structure. The 
peptide-conjugated nanosatellites were next loaded with cyclic guanosine 
monophosphate- adenosine monophosphate (cyclic GMP-AMP, cGAMP) as a potent 
adjuvant. cGAMP was spontaneously associated with the peptide-conjugated 
nanosatellites in phosphate buffered saline solution (PBS) due to the electrostatic 
interaction between highly positive charged peptides and negative charged cGAMP. 
Hydrodynamic diameter of the nanosatellites increases from 64.49 nm to 83.79 nm after 
the E7 and E6 peptide conjugations and 99.31 nm after being loaded with cGAMP 
(figure 4.2 d). Zeta potentials were also dramatically changed after peptide and cGAMP 
conjugation. The nanosatellites carry negative charges due to the AuNP. The zeta 
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potential of nanosatellites was -30.8 mV and became 10.6 mV and -4.2 mV after 
peptide conjugation and cGAMP loading respectively (figure 4.2 e). These data also 
confirmed the successful peptides and cGAMP loaded on the nanosatellites.  
 
4.3.2 Nanosatellite vaccine enhances antigen uptake, induces ISRE promoter 
activity and upregulation of type I IFN-related genes in vitro. 
We first explored whether the nanosatellite can enhance the uptake of the 
antigenic peptide to APC in vitro. The E7 R9F peptides were labeled with a fluorescent 
dye FAM. The E7-FAM conjugated with the nanosatellites, free E7-FAM and PBS 
control were incubated with bone marrow-derived macrophages (BMM) for 2 and 6 
hours. The data clearly show that nanosatellites increase the BMM uptake of the E7 
antigenic peptides compared to the free peptides (figure 4.3a). The higher APC uptake 
positively impacts interferon (IFN) promoter activity and upregulation of type I IFN 
related genes in immune cells. We performed IFN-stimulated response element (ISRE) 
assay using interferon reporter human monocytes (THP1-Blue), which are able to 
produce alkaline phosphatase in a proportion to the amount of IFN stimulation received 
from external triggers. The level of IFN promoter activity was then determined by a 
colorimetric enzyme assay of alkaline phosphatase (Quanti-Blue). 10µg/ml cGAMP with 
or without the nanosatellite vaccine conjugation and other controls were incubated with 
THP1-Blue cells for 16 hours and the supernatants were collected to quantify the 
interferon regulatory factor (IRF)-inducible alkaline phosphatase. Data shows that the 
nanosatellite vaccine effectively induced ISRE promoter activity in monocytes (26.4-
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fold) compared to cGAMP alone (18.9-fold) higher than PBS. Nanosatellite particles 
themselves did not show the stimulation of ISRE promoter activity (figure 4.3b). The 
effective intracellular delivery of cGAMP was also confirmed by the dose-dependent 
higher mRNA levels of type 1-IFN –related genes such as IFNA4, IFNB1, ISG15, 
ISG54, CXCL9, and CXCL10 compared to cGAMP alone. The nanosatellite vaccine at 
the dose of 10µg/ml cGAMP enhances the level of mRNA of IFNA4 (105-fold), 
IFNB1(74-fold), ISG15 (8-fold), ISG54 (39-fold), CXCL9 (2,245-fold), and CXCL10 
(20,177-fold), while cGAMP alone at the same dose increases the level of mRNA only 
16, 37, 5, 22, 488, and 2,160-fold respectively (figure 4.3 c-h). This implies that our 
nanosatellites facilitate the intracellular delivery of cGAMP adjuvant. Our discovery 
agrees with previous report that nanoparticles can promote small molecules 
internalization38,39. To stimulate the mRNA production of the IFN-related genes in 
nucleus, cGAMP must first be delivered to cytosol and bind to STING ligand in the 
endoplasmic reticulum (ER). This suggested that cGAMP can escape from endo-
lysosome to cytosol and bind to the STING ligand in endoplasmic reticulum (ER)14,16. 
cGAMP can dissociate from the peptide-conjugated nanosatellites due to pH change. 
cGAMP is negatively charged at pH 7.4 but switches to a net positive charge under the 
acidic pH in endo-lysosome resulting in dissociation from the peptide-conjugated 
nanosatellites complex and endosomal escape40.   
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4.3.3 Nanosatellite vaccine promotes dendritic cell maturation and IFNb secretion 
from APC in vitro.  
We next investigated the ability of our nanosatellite vaccine on the promotion of 
dendritic cells (DC) maturation, which is a key step for T cell activation. The 
nanosatellite vaccine, cGAMP alone, peptide alone, nanosatellite particles alone were 
incubated with bone marrow derived dendritic cells (BMDC) for 48 hours. The cells were 
harvested and then stained with the maturation markers, CD86 and MHC-II and 
analyzed by flow cytometry. Data show that the nanosatellite vaccine better promoted 
the DC maturation compared to other controls (figure 4.4 a-d). It is possible that the 
nanosatellites delivered cGAMP to BMDC better than cGAMP alone. Although the 
mechanism of cGAMP cellular uptake remains unknown, cGAMP itself is a small 
molecule with negative charges, which is not preferable for the cell to uptake. DC 
maturation is a key step in the generation of potent immune responses because the 
mature DC will become more functional and release many inflammatory cytokines to 
trigger immune cascade to cope with antigens. Mature DC can efficiently process 
antigenic peptides and cross-present the peptide epitope onto MHC-I for further priming 
the CD8+ T cell response21,25.  
We also examined the IFNβ production in murine bone-marrow derived 
macrophages using ELISA. The data also confirm the efficacy of the nanosatellite 
vaccine on type-I IFN production in a dose-dependence (figure 4.4 e).   
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4.3.4 Nanosatellite vaccine travels to lymph nodes in in vivo model 
 It is crucial for the vaccine to efficiently travel to lymph node where the DC 
present the antigenic peptides and activate CD8+ T cells 41. We took the advantage of 
the present of iron oxide nanoparticles in our vaccine to visualize vaccine biodistribution 
in lymph nodes. It is well-documented that iron oxide nanoparticles can lower T2 
relaxation time and darken the magnetic resonance (MR) images42,43. MR images 
clearly show that 4 hours post subcutaneous injection of the nanosatellite vaccine at tail 
base of C57BL/6 mice, the inguinal and popliteal lymph nodes became darker and the 
vaccine remained in the lymph nodes longer than 24 hours after injection (figure 4.5). 
Our nanosatellite vaccine can accumulate in the lymph node within 4 hours after S.C 
injection implying that the vaccine enters the lymphatic system directly rather than be 
uptaken by APC initially because it generally takes approximately 24 hours for APC to 
arrive lymph nodes21,44. Moreover, the longer the resident time of the vaccine in the 
lymph node, the higher the chance for naïve T cells to come to contact with the DC, 
which would result in more robust T cell activation45. This perspective justifies the use of 
nanoparticle for antigenic peptide and small molecule adjuvant delivery. The 
nanosatellite vaccine can carry the peptides to the lymph nodes and promote the T cell 
activation, while soluble peptides may not be able to reach the lymphatic system or 
rapidly eliminated out of the body resulting in low immune response.  
  
106	
	
4.3.5 Nanosatellite vaccine suppressed tumor growth and boost E7-specific anti-
tumor immunity in a mouse xenograph model 
 After the nanosatellite vaccine demonstrated a great efficacy in vitro, we 
continued investigating the efficacy of the vaccine for tumor suppression in vivo. 0.4 x 
106 cells of MOC2, mouse oral cancer cell line, were subcutaneously implanted into the 
neck of C57B/6 mice on day zero. The mice were treated with PBS, cGAMP alone, or 
the nanosatellite vaccine (vaccine R9F), 3 weekly doses (figure 4.6a). The mice treated 
with the nanosatellite vaccine R9F on day 25 show significant smaller tumor burden 
than the mock and other control treatments (figure 4.6b). The tumors were harvested for 
type I IFN-related genes and E7- specific T cell activation studies. The nanosatellite 
vaccine R9F potently promoted the production of ifna4 and ifnb1 (figure 4.6c), which is 
in a good agreement with our in vitro assay. cGAMP showed some weak effect on the 
type I IFN and tumor suppression due to the rapid degradation. To investigate the E7- 
specific T cell response, tumor infiltrating lymphocytes (TIL) were isolated from the 
tumors using ficoll gradient centrifugation46. TIL were then stained with a tetramer 
recognizing H-2Db-restricted HPV16 E7 epitope RAHYNIVTF and analyzed by flow 
cytometry. Interestingly, the vaccine dramatically improved the percentage of E7-
specific CD8+ T cells compared to the PBS and cGAMP treated groups (figure 4.6d). 
To improve the efficacy of the nanosatellite vaccine in tumor suppression, we 
further replaced the E7 R9F peptide with E7 Q19D (Vaccine Q19D), which has longer 
sequence of amino acids. The mice were vaccinated, or received E7 Q19D/E6 peptides 
alone, cGAMP alone, anti PD-L1 antibody alone or a mock treatment. The treatments 
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were started 3 days after tumor implantation and the mice received vaccine Q19D, 
cGAMP, peptides, PBS once a week for 3 weeks or received anti PD-L1 
intraperitoneally twice a week for 3 weeks (figure 4.7a). The data show that vaccine 
strongly suppressed tumor growth compared to other treated groups. It was observed 
that after the second vaccination, the tumor burden started to diminish, while the tumors 
in other groups progress quickly (figure 4.7 b and d). The tumor volumes of the 
vaccinated mice were 6.3 times smaller than the mice that received the mock treatment 
and 3.6 times smaller than those received the cGAMP as an adjuvant alone on day 21. 
Anti PD-L1 antibody and E7/E6 peptides failed to suppress the tumor growth (figure 4.7 
b and d). Moreover, the vaccinated mice showed the better survival rate compared to 
other control groups. The medians of survival were 31, 28, and 21 days in the 
vaccinated, cGAMP-treated, and other groups respectively (figure 4.7c). 
We also performed real-time PCR and FACs from tumor tissues and TILs to 
prove the effect of the nanosatellite vaccine Q19D.  Similar to our previous data, the 
nanosatellite vaccine Q19D exhibited the strongest type I IFN production compared to 
other group of treatments (figure 4.8 a-b). Flow cytometry analysis of TILs demonstrated 
that the nanosatellites vaccine Q19D robustly activated E7-specific CD8+ T cells (figure 
4.8 c-d).  This confirms that the nanosatellite vaccine successfully delivered the E7/E6 
antigenic peptides and cGAMP to the APC. It is assumed that E7/E6 peptides bound 
with the gold satellites by Au-thiol covalent bonding could be cleaved  by glutathione 
inside the lysosomes and escape to the cytosol after the cell uptake47. These APC 
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subsequently cross-presented the peptides to CD8+ T cells.  These primed cytotoxic T 
lymphocytes (CTL), which can eliminate the E7/E6 overexpressed tumors robustly.  
We further investigated the effect of the nanosatellite vaccine on a resistant 
mouse oral cancer cell line overexpressing SOX2 oncogenic protein, which dampens 
the type I interferon by increasing the degradation of STING protein. The treatment 
schedule remains the same with the previous study (figure 4.9 a). The data show that 
the combination therapy between the nanosatellite vaccine (Q19D) and anti PD-L1 
antibody is very effective on SOX2 overexpressed tumor inhibition compared to other 
groups of treatments (figure 4.9 b-c). The combination treatment can strongly suppress 
tumor growth because of the dual mechanism. The nanosatellite vaccine promotes T 
cell inflamed microenvironment and directs more T cell and APC to the tumor bed, while 
the anti- PD-L1 antibody prevents T cell from exhaustion. The vaccine alone and anti 
PD-L1 antibody alone can also suppress the tumor growth at a certain level. 
Interestingly, the anti PD-L1 antibody seems to be more effective on SOX2 
overexpressed tumor than SOX2 negative tumor in the previous experiment. It may be 
because the SOX2 tumor has higher level of PD-L1 than SOX2 negative tumor.  
  
4.3.6 Nanosatellite vaccine stimulates type I IFN innate immunity to attack cancer 
cells in vivo. 
  We continued to explore the mechanism underlining anti-tumor effect of the 
vaccine. Tumor tissues were harvested for real-time qPCR assay investigating for type I 
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IFN-related gene regulations and for western blot analysis for proteins. It is clear that 
vaccine promoted the up-regulation of type I IFN mRNA levels such as Ifna4, Ifnb1 and 
Cxcl10, which was in a good agreement with our in vitro study. Furthermore, western 
blots demonstrated that the vaccine crucially promoted the phosphorylation of tank 
binding kinase1 (TBK1), which is a key player in STING pathway (figure 4.10). It has 
been well known that cyclic di-nucleotides (CDN) bind to STING ligands and activate 
STING signaling through the TBK1/IRF-3 axis and subsequently induce the expression 
of IFN-b14,48,49. Our real-time PCR and western blot data suggest that the nanosatellite 
vaccine was uptaken by immune cells and cGAMP activated the STING/TBK1/IRF3 
pathway as mentioned previously. The complex trafficked to nucleus and activated the 
type I IFN-related gene transcription. In contrast, cGAMP alone showed low level of 
mRNA and weak phosphorylated TBK1 due to mild activation on STING pathway. 
Because the tumor tissues were harvested two weeks after the last injection, cGAMP 
may already been degraded or eliminated from the body. Additionally, cGAMP is a 
water soluble small molecule and carries negative charges at physiological pH, which is 
difficult to pass lipid bilayer of plasma membrane. Moreover, the highly soluble small 
molecule cGAMP can diffuse from the site of administration easily and go to blood 
stream without entering the lymphatic system. With these characteristics, it is not 
feasible to use cGAMP alone as an adjuvant without effective delivery system in vivo 
regardless of their strong potency to activate STING ligand.    
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 4.4 Conclusions 
We successfully developed a potent nanosatellite vaccine composed of E7/E6 
oncogenic peptides and cGAMP for HPV+ HNSCC treatment. The peptides were 
conjugated on the surface of the nanosatellites with high density. In vitro results show 
that the nanosatellite vaccine promotes DC maturation determining by the expression of 
CD86, MHC-II, and the upregulation of type I IFN signature genes, which are required 
for further T cell activation. Nanosatellite particles also enhance the uptake of peptides 
in BMM. The nanosatellite vaccine can travel to lymph nodes after S.C injection in mice 
and activate immune responses to suppress the tumor growth significantly. The 
immunized mice showed higher type I IFN mRNA level and E7 specific T cell in tumor 
tissues. Therefore, this nanosatellite vaccine is a promising candidate for future HPV+ 
HNSCC treatments 
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4.5 Materials and methods 
Iron oxide(III) (FeO(OH), hydrated, catalyst grade) oleic acid (technical grade, 90%), 1-
octadecene (technical grade, 90%), anhydrous tetrahydrofuran (THF, 99.8%), 
ammonium iron(II) sulfate hexahydrate (Fe(NH4)2(SO4)2.6H2O, ACS reagent, 99%), 
sodium sulfide (Na2S), Gold (III) Chloride solution (HAuCl4 in HCl), nitric acid (ACS 
reagent, 70%), and hydrochloric acid (ACS reagent, 37%), were purchased from 
Aldrich. Modified E7 (R9F) peptide (CSKKK-RAHYNIVTF), and modified E6 (Q15L) 
peptide (CSKKK-QLLRREVYDFAFRDL) 95% purity were purchased from Elim 
biopharm (USA). Acetylthio-PEG5k-Maleimide was purchased from NANOCS (USA). 
2’3’ cGAMP (cyclic [G(2’,5’)pA(3’,5’)p]) was purchased from Invivogen (USA).  
 
Synthesis of nanosatellites particles 
The iron oxide (IONP) core particles of the nanosatellites were synthesized by thermal 
decomposition as previously report49. The core particles were subsequently coated by a 
diblock copolymer (PEO-b-gMPS). The coating method has been previously report50. 
The coated IONP were characterized by transmission electron microscope (TEM) (Jeol 
1400 plus). Gold sulfide nanoparticles (Au2SNP) were synthesized by using sodium 
sulfide (Na2S) and chloroauric acid (HAuCl4) solution as a previous report32 with slightly 
modifications. 2 mM HAuCl4 solution was rapidly mixed with 1mM of aged Na2S solution 
at the volume ratio of 7:12. The color of mixed solution immediately turned from yellow 
to brownish. Au2SNP were kept in 4 °C. The Au2SNP were characterized by TEM. To 
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fabricate the nanosatellite particles (NS), 1mg Fe of IONP (15nm) were added into 3 ml 
of Au2SNP (2nm) solution and mixed homogenously incubated on a rocking platform for 
30 minutes and stored at 4 °C.  The nanosatellite solution was filtered by 0.45 µm 
syringe filter before used.  
Gold and iron concentration measurement  
The nanosatellites were digested in aqua regia solution (Hydrochloric acid and Nitric 
acid 3:1) overnight. The digested nanosatellites were diluted in Milli Q water. The gold 
and iron concentrations were measured by using Inductively Coupled Plasma–Optical 
Emission Spectroscopy (ICP-OES) (Perkin-Elmer Optima 2000 DV). Standard gold and 
iron elements were used to generate calibration curves.  
Nanosatellite vaccine synthesis (E7, r9f and E6 peptide, and cGAMP adjuvant 
stepwise conjugations with NS) for in vitro experiment 
Modified E7, r9f, peptide (0.5mM, 1ml) was incubated with Acetylthio-PEG5k-Maleimide 
(0.2mM, 1ml) for 2 hours in endotoxin-free water. A drop of 3% HCl solution was added 
into the solution to activate the thiol functional group. The active solution (200µl) was 
homogeneously mixed with the NS (Fe 0.05 mg/ml) and incubated at room temperature 
for 2 hours. The modified E7 peptides conjugated with NS were purified using a magnet 
separator. The supernatant was taken to quantified the concentration of the peptide by 
using LavaPep (Gel company, USA). The modified E6 peptide (0.5mM, 1ml) was 
reacted with Acetylthio-PEG5k-Maleimide (0.2mM, 1ml) for 2 hours and subsequently 
deprotected the thiol functional group. The E7-NS were further conjugated with 
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deprotected E6 peptide (10µl) using the same procedure with the modified E7 peptide. 
The final product was purified overnight using a magnet separator (Nanosep). The 
unbound E6 in the supernatant was quantified by using LavaPep.  
 2’3’ cGAMP was added into the peptides-conjugated NS at different concentrations. 
 
Nanosatellite vaccine synthesis (E7, q19d and E6 peptide, and cGAMP adjuvant 
stepwise conjugations with NS) for in vivo experiment 
Modified E7, q19d, peptide (0.36 µmol) was incubated with Acetylthio-PEG5k-Maleimide 
(0.2µmol) for 2 hours in PBS. 2 µl HCL (1.2 mM) was added into the solution to activate 
the thiol functional group. The active solution was homogeneously mixed with the NS 
(Fe 0.28 mg/ml) and incubated at room temperature for 2 hours. The modified E7 
peptides conjugated with NS were purified using a magnet separator overnight. The 
supernatant solution was taken to quantify the concentration of the peptide by using 
LavaPep (Gel company, USA). The modified E6 peptide (0.4µmol) was reacted with 
Acetylthio-PEG5k-Maleimide (0.2µmol) for 2 hours and subsequently deprotected the 
thiol functional group. The E7-NS were further conjugated with deprotected E6 peptide 
(10µl) using the same procedure with the modified E7 peptide. The final product was 
purified overnight using a magnet separator (Nanosep). The unbound E6 in the 
supernatant was quantified by using LavaPep.  2’3’ cGAMP (0.7µmol in PBS) was 
added into the peptides-conjugated NS. The final E7 and E6 peptide concentration were 
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18 nmol and 0.5 nmol respectively. The final product was used without further 
purification. 
Nanoparticle characterizations 
Nanoparticles were characterized by TEM. TEM imaging were prepared by the solvent 
evaporation method. Briefly, the solution (5 µL) of each sample were dropped onto 
carbon-coated copper TEM grids and allowed to dry overnight. TEM images were 
acquired on a transmission electron microscope (TEM, Jeol 1400 plus, 80 kV). 
Hydrodynamic diameters and zeta potential of nanoparticles were measured by Zeta 
Sizer (Malvern).  
ISRE experiments  
THP1- blue cells were purchased from Invivogen (USA), and were cultured in RPMI 
media supplemented with 10% FBS, 1% penicillin and streptomycin antibiotics, 
Normocin and Zeocin according to the company protocol. The 0.1x106 cells were 
seeded into each 96 well-plate with the 180µl of the completed media and 20µl of media 
control, cGAMP (1µg/ml or 10µg/ml final concentration), nanosatellites particles, or the 
vaccine were added. The cGAMP in the vaccine had the same final concentration with 
the cGAMP control groups. The cells were incubated with the treatment for 16 hours. 
The supernatants were taken out and incubated with Quanti-Blue according to the 
company protocol and measured the absorption at 655nm.  
Quantitative Real-time PCR 
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THP1-blue cells were seeded at one million cells/well in a 6-well plate. The cells were 
treated 16 hours with media alone, nanosatellites alone, cGAMP (1µg/ml or 10µg/ml 
final concentration), or the vaccine with cGAMP (1µg/ml or 10µg/ml final concentration). 
The RNA were isolated and purified using the Qiashredder kit and RNEasy Plus kit 
(Qiagen). The concentrations of RNA were quantified by NanoDrop. cDNA were 
generated by High Capacity RNA-to-cDNA kit (Applied Biosystems). RT-PCR were 
subsequently performed.  
Ifnb1 Elisa assay of bone marrow-derived macrophages 
Bone marrow-derived macrophages (BMM) were obtained from C57BL/6 mice at the 
age of 8 week old. BMM were incubated at 37 °C and 5% CO2 incubator in RPMI media 
supplemented with 30% L929 media, 20% heat-inactivated FBS, and 1% penstrep. The 
new media were added on day 3. 0.5 x 106 cells were seeded into 12 well-plate 
overnight before being incubated with PBS, cGAMP alone (10ug/ml), nanosatellites 
alone, and the vaccine. Lipopolysaccharide (LPS) was used as a positive control. The 
cell supernatant was collected at 24 hours after incubation for IFN-b quantification 
assay (Biolegend) according to the company protocol.   
Dendritic cell maturation assay 
Bone marrow-derived dendritic cells (BMDC) were obtained from C57BL/6 mice of 8 
week old. The cells were cultured in RPMI media supplemented with 10% heat-
inactivated FBS, 1% penstrep, glutamine, non-essential amino acid, sodium pyruvate, 
2-mercaptoethanol, and 10 ng/ml GM-CSF (Peprotech,USA). The new completed 
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media supplemented with 20 ng/ml GM-CSF were added on day 3. 0.5 x 106 cells were 
seeded into 12 well-plate on day 6 and incubated overnight. The cells were then treated 
with PBS, cGAMP alone (10ug/ml), the peptides, vaccine (cGAMP 10ug/ml) or 
Lipopolysaccharide (200 ng/ml) (eBiosciences). 48 hours after incubation, the cells were 
washed 3 times with PBS before harvest. The Fc blocker CD16/32 (clone 93, 
eBiosciences) was used to block non-specific binding before staining with the surface 
marker antibodies. The cells were then staining with MHC-II-FITC (clone M5/114.15.2, 
eBiosciences) and CD86 PE (clone GL1, eBiosciences) for maturation markers, and 
DAPI for viability. The data were analyzed using Flow Jo software.   
Nanosatellite vaccine uptake study in BMM 
E7 peptide labeled with 6-FAM was conjugated with nanosatellites for cell uptake study 
compared with free E7-FAM peptide. Bone marrow derived macrophages isolated from 
C57BL/6 mice’ femurs and tibias and were cultured for 6 days in 10 mm non-tissue 
culture dishes supplemented with conditioned RPMI media with 30% L929 media, 20% 
FBS, 1% penicillin and streptomycin. On day 6, 4 x 104 cells were seeded in to a black 
96-well plate overnight to let the cells attach to the plate and supplemented with the 
conditioned RPMI media without L929. Next day, the media was removed and replaced 
with phenol red-free and FBS free RPMI media. Nanosatellite vaccine and other 
controls were incubated with the cells for 2 and 6 hours and then the cells were washed 
3 time with PBS. The fluorescent signal was read at the excitation 490 nm and emission 
520 nm.  
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Magnetic resonance imaging (MRI) of lymph nodes in mice 
The MRI were preformed using Agilent 7 tesla at TE= 30ms and TR= 4,000ms 
NS conjugated with the modified E7 peptides were administered to C57BL/6 mice via 
subcutaneous injection at tail-base at the iron concentration 50µg/mouse. The mice 
were on isoflurane vaporizer to maintain anesthetic condition. The mice were imaged 
before the NS injection to serve as self-control, at 4 hours, and 24 hours post-injection.  
In vivo immunization and cancer treatment studies. 
The animal studies were followed a protocol approved by Institutional Animal Care & 
Use Committee (IACUC) at University of Michigan. C57BL/6 mice of age 6-8 weeks 
(Jackson Laboratory) were subcutaneously implanted with 0.4x 106 MOC2 cells at the 
neck area on day zero. The mice (5/group) were immunized with PBS, 2’3’ cGAMP (50 
µg/100 µl), peptides (18.5 nmol/100 µl), nanosatellite vaccine (2’3’ cGAMP 50ug and 
peptide 18.5 nmol conjugated with the NS/100 µl), anti PD-L1 antibody (100µg/100µl) 
(BioXcell, USA). 100 µl of anti PD-L1 antibody was administered to the mice by 
intraperitoneal injection twice a week. The other formulations (100 µl) were administered 
by subcutaneous injection at the tail base once a week for 3 weeks. The tumors were 
monitored and the volume of the tumors were calculated by 0.52 x length x width2.  
Flow cytometric characterization of tumor-infiltrating lymphocytes.  
Excised tumors were mechanically dissociated and subjected to Ficoll-Paque density 
gradient centrifugation. Separated TILs were washed twice in RPMI and counted. The 
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following antibodies were used for flow cytometry: anti-CD3 (BD Biosciences, clone 
17A2), anti-CD4 (Biolegend, clone RM4-5), anti-CD8 (Biolegend, clone 53-6.7), anti-
CD279 (Biolegend, clone 29F.1A12), and a tetramer recognizing H-2Db-restricted 
HPV16 E7 epitope RAHYNIVTF (NIH tetramer core). Cell viability was assessed using a 
fixable viability dye eFluor 780 (Thermo Fisher Scientific). All staining was done in 
FACS buffer (2% FBS in PBS). Acquisition and compensation was performed on 
Beckman Coulter CyAn ADP. FlowJo V10 software was used to analyze the data. 
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Primers for quantitative real-time PCR assays 
Gene Name Forward (5'->3') Reverse (5'->3') Species 
cxcl10 5’-AATGAGGGCCATAGGGAAGC 5’-AGCCATCCACTGGGTAAAGG Mm 
cxcl9 5’-GAGCAGTGTGGAGTTCGAGG 5’-TCCGGATCTAGGCAGGTTTG Mm 
Ifnb1 5’-CCAGCTCCAAGAAAGGACGA 5’-CGCCCTGTAGGTGAGGTTGAT Mm 
gapdh 5′-TGCACCACCAACTGCTTAG 5′-GGATGCAGGGATGATGTTC Mm 
pan-Ifna 5’-CCTGAGAGAGAAGAAACACAGCC 5’-TCTGCTCTGACCACYTCCCAG Mm 
hprt1 5’-GATTAGCGATGATGAACCAGGTT 5’-CCTCCCATCTCCTTCATCACA Mm 
IFNB1  5'-CATTACCTGAAGGCCAAGGA 5′-CAATTGTCCAGTCCCAGAGG Hs 
IFNA4  5'-CCTAGAGGCCGAAGTTCAAG 5'-TTGTGCCAGGAGTATCAAGG Hs 
CXCL10 5'- CTCCAGTCTCAGCACCATGA 5'- GCTCCCCTCTGGTTTTAAGG Hs 
CXCL9 5'-GTGGTGTTCTTTTCCTCTTGGG 5'-ACAGCGACCCTTTCTCACTAC Hs 
ISG54 5′-ACGGTATGCTTGGAACGATTG-3′ 5′-AACCCAGAGTGTGGCTGATG Hs 
GAPDH  5′-TTCGACAGTCAGCCGCATCTTCTT-3′ 5′-CAGGCGCCCAATACGACCAAATC Hs 
HPRT1 5'- ATGCTGAGGATTTGGAAAGG 5'- CAGAGGGCTACAATGTGATGG Hs 
ISG15  5’-CTGAGAGGCAGCGAACTCAT-3’ 5’-AGCATCTTCACCGTCAGGTC-3’ Hs 
120	
	
4.6 Acknowledgements 
This work has been done in collaboration with Yee Sun Tan, Xiaobo Luo, Xinyi Zhao, 
Blake Heath, Toktam Moghbeli, Yu Lei, Hongwei Chen, and Duxin Sun. We thank Dr. 
David Mooney for providing the MOC2-E6/E7 cell line.  
This work is part of the manuscript conducted by Tan Y.S**., Sansanaphongpricha S**., 
Xie Y., Donnelly C, Luo X., Zhao X., Bellile E., Heath B.R., Chen Q., Polverini P.J., 
Carey T.E., Nor J., Young S.W.M., Ferris R., Wolf  G.T., Sun D.*, Lei Y.* A Type I 
Interferon-inducing Nanosatellite Vaccine Mitigates Immune Suppression in Head and 
Neck Squamous Cell Carcinoma, in submission. 
121	
	
4.7 References: 
 
1. Ferlay, J. et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in 
GLOBOCAN 2012. Int. J. Cancer 136, E359–E386 (2015). 
2. Sanderson, R. J. & Ironside, J. A. D. Squamous cell carcinomas of the head and neck. BMJ 325, 
822–7 (2002). 
3. Siegel, R., Miller, K. & Jemal, A. Cancer statistics , 2015 . CA Cancer J Clin 65, 29 (2015). 
4. Zhao, Y. et al. Targeted nanoparticle for head and neck cancers: overview and perspectives. 
Wiley Interdiscip. Rev. Nanomedicine Nanobiotechnology e1469 (2017). doi:10.1002/wnan.1469 
5. Rothenberg, S. M. & Ellisen, L. W. The molecular pathogenesis of head and neck squamous cell 
carcinoma. J. Clin. Invest. 122, 1951–7 (2012). 
6. Weber, R. et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N. 
Engl. J. Med. 363, 24–35 (2010). 
7. Chaturvedi, A. K. et al. Human papillomavirus and rising oropharyngeal cancer incidence in the 
United States. J. Clin. Oncol. 29, 4294–4301 (2011). 
8. Seiwert, T. Y., Salama, J. K. & Vokes, E. E. The chemoradiation paradigm in head and neck 
cancer. Nat. Clin. Pract. Oncol. 4, 156–171 (2007). 
9. Ferris, R. L. et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N. 
Engl. J. Med. 375, 1856–1867 (2016). 
10. Seiwert, T. Y. et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or 
metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, 
multicentre, phase 1b trial. Lancet Oncol. 17, 956–965 (2016). 
11. Starr, P. Encouraging Results for Pembrolizumab in Head and Neck Cancer. Am. Heal. drug 
benefits 8, 16 (2015). 
12. Ferris, R. L. Immunology and immunotherapy of head and neck cancer. J. Clin. Oncol. 33, 3293–
3304 (2015). 
13. Zitvogel, L., Galluzzi, L., Kepp, O., Smyth, M. J. & Kroemer, G. Type I interferons in anticancer 
immunity. Nat Rev Immunol 15, 405–414 (2015). 
14. Dubensky, T. W., Kanne, D. B. & Leong, M. L. Rationale, progress and development of vaccines 
utilizing STING-activating cyclic dinucleotide adjuvants. Ther. Adv. Vaccines 1, 131–43 (2013). 
15. Woo, S. R., Corrales, L. & Gajewski, T. F. The STING pathway and the T cell-inflamed tumor 
microenvironment. Trends Immunol. 36, 250–256 (2015). 
16. Barber, G. N. STING: infection, inflammation and cancer. Nat. Rev. Immunol. 15, 760–770 (2015). 
17. Corrales, L. et al. Direct Activation of STING in the Tumor Microenvironment Leads to Potent and 
Systemic Tumor Regression and Immunity. Cell Rep. 11, 1018–1030 (2015). 
18. Leoncini, E. et al. Induction of tumor regression by intratumoral STING agonists combined with 
anti-programmed death-L1 blocking antibody in a preclinical squamous cell carcinoma model. 
Head Neck 36, 1391 (2017). 
19. Marur, S., D’Souza, G., Westra, W. H. & Forastiere, A. A. HPV-associated head and neck cancer: 
A virus-related cancer epidemic. Lancet Oncol. 11, 781–789 (2010). 
20. Schoenfeld, J. D. Immunity in head and neck cancer. Cancer Immunol. Res. 3, 12–7 (2015). 
21. Bachmann, M. F. & Jennings, G. T. Vaccine delivery: a matter of size, geometry, kinetics and 
122	
	
molecular patterns. Nat. Rev. Immunol. 10, 787–96 (2010). 
22. Liu, H. & Irvine, D. J. Guiding principles in the design of molecular bioconjugates for vaccine 
applications. Bioconjug. Chem. 26, 791–801 (2015). 
23. Moon, J. J., Huang, B. & Irvine, D. J. Engineering nano- and microparticles to tune immunity. Adv. 
Mater. 24, 3724–46 (2012). 
24. Hamdy, S., Haddadi, A., Hung, R. W. & Lavasanifar, A. Targeting dendritic cells with nano-
particulate PLGA cancer vaccine formulations. Adv. Drug Deliv. Rev. 63, 943–955 (2011). 
25. Gamvrellis, A. et al. Vaccines that facilitate antigen entry into dendritic cells. Immunol. Cell Biol. 
82, 506–516 (2004). 
26. Irvine, D. J., Hanson, M. C., Rakhra, K. & Tokatlian, T. Synthetic Nanoparticles for Vaccines and 
Immunotherapy. Chem. Rev. 115, 11109–11146 (2015). 
27. Chithrani, B. D., Ghazani, A. a & Chan, W. C. W. Determining the size and shape dependence of 
gold nanoparticle uptake into mammalian cells. Nano Lett. 6, 662–8 (2006). 
28. Smith, D. M., Simon, J. K. & Baker, J. R. Applications of nanotechnology for immunology. Nat. 
Rev. Immunol. 13, 592–605 (2013). 
29. Gravitz, L. A fight for life that united a field. Nature 478, 163–164 (2011). 
30. Caudle, A. S., Yang, W. T., Mittendorf, E. A. & Kuerer, H. M. The impact of nanoparticle ligand 
density on dendritic-cell targeted vaccines. Biomaterials 32, 3094–3105 (2011). 
31. Chang, T. Z., Stadmiller, S. S., Staskevicius, E. & Champion, J. A. Effects of ovalbumin protein 
nanoparticle vaccine size and coating on dendritic cell processing. Biomater. Sci. 5, 223–233 
(2017). 
32. Chen, H. et al. Facile Fabrication of Near-Infrared-Resonant and Magnetic Resonance Imaging-
Capable Nanomediators for Photothermal Therapy. ACS Appl. Mater. Interfaces 7, 12814–12823 
(2015). 
33. Volatron, J. et al. Ferritin Protein Regulates the Degradation of Iron Oxide Nanoparticles. Small 1–
13 (2016). doi:10.1002/smll.201602030 
34. Mazuel, F. et al. Massive Intracellular Biodegradation of Iron Oxide Nanoparticles Evidenced 
Magnetically at Single-Endosome and Tissue Levels. ACS Nano 10, 7627–7638 (2016). 
35. Alric, C. et al. The biodistribution of gold nanoparticles designed for renal clearance. Nanoscale 5, 
5930–9 (2013). 
36. Longmire, M., Choyke, P. L. & Kobayashi, H. Clearance properties of nano-sized particles and 
molecules as imaging agents: considerations and caveats. Nanomedicine (Lond). 3, 703–717 
(2008). 
37. Chou, L. Y. T., Ming, K. & Chan, W. C. W. Strategies for the intracellular delivery of nanoparticles. 
Chem. Soc. Rev. 40, 233–245 (2011). 
38. Shi, J., Kantoff, P. W., Wooster, R. & Farokhzad, O. C. Cancer nanomedicine: progress, 
challenges and opportunities. Nat. Rev. Cancer 17, 20–37 (2016). 
39. Takai, Y., Nishiyama, K., Yamamura, H. & Nishizuka, Y. Guanosine 3’5’-Monophosphate-
dependent Protein Kinase from Bovine Cerebellum. J. Biol. Chem. 250, 4690–4695 (1975). 
40. Fan, Y. & Moon, J. J. Nanoparticle Drug Delivery Systems Designed to Improve Cancer Vaccines 
and Immunotherapy. Vaccines 3, 662–85 (2015). 
41. Laurent, S. et al. Magnetic iron oxide nanoparticles: synthesis, stabilization, vectorization, 
physicochemical characterizations, and biological applications. Chem. Rev. 108, 2064–110 
(2008). 
42. Mornet, S. et al. Magnetic nanoparticle design for medical applications. Prog. Solid State Chem. 
34, 237–247 (2006). 
43. Manolova, V. et al. Nanoparticles target distinct dendritic cell populations according to their size. 
123	
	
Eur. J. Immunol. 38, 1404–1413 (2008). 
44. Bousso, P. T-cell activation by dendritic cells in the lymph node: lessons from the movies. Nat. 
Rev. Immunol. 8, 675–84 (2008). 
45. English, D. & Andersen, B. R. Single-step separation of red blood cells, granulocytes and 
mononuclear leukocytes on discontinuous density gradients of Ficoll-Hypaque. J. Immunol. 
Methods 5, 249–252 (1974). 
46. Hong, R. et al. Glutathione-mediated delivery and release using monolayer protected nanoparticle 
carriers. J. Am. Chem. Soc. 128, 1078–1079 (2006). 
47. Chiu, Y. H., MacMillan, J. B. & Chen, Z. J. RNA Polymerase III Detects Cytosolic DNA and 
Induces Type I Interferons through the RIG-I Pathway. Cell 138, 576–591 (2009). 
48. Zhang, X. et al. Cyclic GMP-AMP containing mixed Phosphodiester linkages is an endogenous 
high-affinity ligand for STING. Mol. Cell 51, 226–235 (2013). 
49. Chen, H. et al. Highly crystallized iron oxide nanoparticles as effective and biodegradable 
mediators for photothermal cancer therapy. J. Mater. Chem. B 2, 757 (2014). 
50. Chen, H. et al. Biocompatible polysiloxane-containing diblock copolymer PEO-b-PγMPS for 
coating magnetic nanoparticles. ACS Appl. Mater. Interfaces 1, 2134–2140 (2009). 
 
 
 
 
 
  
124	
	
 
 
 
 
 
 
  
Figure 4.1. Nanosatellite particles compositions. a) and b) are TEM images of gold sulfide and 
iron oxide nanoparticles respectively. c-f) represent the TEM images of the nanosatellites with 
different molar ratios of gold sulfide and iron oxide nanoparticles. g- i) the bar graphs show the 
number of gold nanoparticles/iron oxide core when the different molar ratios were used to make 
the nanosatellites. The most stable nanosatellite system with the decent number of the gold 
sulfide nanoparticles is 1:3 molar ratio, which was used for the further conjugation with peptides. 
Scale bars represent 20 nm.   
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Scheme 4.1. a cartoon picture describes the process of the E7/E6 antigenic peptides and 
cGAMP adjuvant conjugation. The gold sulfide nanoparticles were attached to the iron oxide core 
by a unique polymer MPS-b-PEO. Modified E7/E6 peptides were covalently conjugated with the 
gold satellites via maleimide-thiol functional PEG linkers. The cGAMP adjuvant was 
electrostatically bound to the E7/E6 peptide in the last step.      
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Figure 4.2. Nanoparticle characterizations. a) and b) show the TEM images of the nanosatellites 
with a diameter ca. 25 nm. c) a calibration curve of the peptide conjugation for determining the 
conjugation efficiency. The conjugation efficiency is 91%. d) Hydrodynamic diameter measured 
by a dynamic light scattering method. The Dh slightly increase after peptide and cGAMP 
conjugation. e) the chart demonstrates the surface charges of the naked nanosatellites (blue), 
peptide conjugated NS (red), and cGAMP conjugated NS (green). The surface charges 
dramatically changed in each step indicating the successful conjugation.     
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Figure 4.3. In vitro assays show nanosatellites enhance peptide uptake, promote ISRE activity 
and upregulate IFN-I related genes.  a) Nanosatellites enhance the antigenic fluorescent labelling 
peptide E7-FAM uptake in BMM after 2 and 6 hours of incubations. b) ISRE promoter activity in 
THP1- blue reporter cells were effectively induced by the nanosatellite vaccine after the cells 
were incubated with the nanosatellite vaccine compared to cGAMP alone, nanosatellite alone or 
PBS. c-h) THP1 cells were treated with different doses of cGAMP with or without the 
nanosatellites delivery vehicle. The mRNA abundance of the indicated IFN-I signaling genes were 
quantitated by real time PCR. Nanosatellite vaccine strongly induces the type I FN related genes 
upregulation in a dose-dependence of cGAMP.  
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Figure 4.4. DC maturation assays. a-b) demonstrate that the nanosatellite vaccine induces the 
expression of the maturation markers of DC such as MHC-II and CD86. The red color represents 
PBS control and the blue color indicates the different treatments for each group. c-d) represent 
the mean fluorescence intensity of the flow cytometry analysis of MHC-II and CD86 expression on 
DC after being incubated with E7/E6 peptides, cGAMP, and the vaccine. The assays were done 
in triplicates. e) Nanosatellite vaccine also promotes the secretion of IFNβ in BMDM measured by 
ELISA 
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Figure 4.5. In vivo magnetic resonance images of the inguinal popliteal lymph nodes at the pre-
injection and 4- and 6- hours post subcutaneous injection at the tail base. The images clearly 
show that the nanosatellite vaccine can travel to the inguinal and popliteal lymph nodes within 4 
hours after injection and accumulate there at least 24 hours. In a) to c), the highlighted red circle 
refers to the inguinal lymph node, while in d) to f), the highlighted region is the popliteal lymph 
node. 
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Figure 4.6. In vivo vaccination in tumor-bearing mice. a) a schematic picture describes 
vaccination schedule. The treatments stared 3 days after tumor implantation of MOC2 cells. Other 
controls were also given at the similar schedule with the vaccine R9F. b) Tumor measurements of 
mice with indicated treatments.The nanosatellite vaccine R9F significantly suppress the tumor 
growth in mouse xerograph model. c) The mRNA were isolated from the tumor tissue and 
quantified by real-time PCR. The vaccine R9F promotes the upregulation of Ifna4 and Ifnb1 in 
vivo compared to other controls.  d)  Flow cytometry analysis of E7-specific CTL isolated from 
tumors. The vaccine R9F proves effective to boost the E7-specific CD8+ T cell immunity. 
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Figure 4.7. In vivo study of tumor-bearing mice with vaccine Q19D. a) A schematic picture 
describes vaccination and anti PD-L1 antibody injection schedule. The treatments started 3 days 
after subcutaneous tumor implantation. Other controls were also given at the similar schedule with 
the vaccine Q19D. b) Tumor measurements of mice with the indicated treatment. The nanosatellite 
vaccine Q19D significantly reduces tumor burden in mouse xerograph model. c) Kaplan-Meier 
survival curves of the mice described in a) and b). Nanosatellite vaccine Q19D shows longer 
survival of the tumor-bearing mice compared to other groups of treatments. d) The charts show the 
individual tumor growth details of each mouse from figure b across 5 groups, PBS control, 
nanosatellite vaccine (Q19D), peptides, cGAMP, and anti PD-L1 antibody treatments. 
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Figure 4.8. a-b) the mRNA levels of pan- ifna4 and ifnb1 significantly increase the mice treated with 
vaccine Q19D. c-d) Flow cytometry analysis of E7-specific CTL isolated from tumors. The vaccine 
Q19D effectively promotes the E7-specific CD8+ T cell immunity. 
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Figure 4.9. In vivo study of the SOX 2-positive tumor-bearing mice. The treatment in each group was 
started at day 3 after the tumor implantation. a) a cartoon picture demonstrates the treatment timeline. 
All treatments were given once a week for three weeks but anti PD-L1 antibody was given twice a 
week for three week. b) the combination therapy shows significant tumor suppression compared to 
other groups at day 25 after tumor implantation. The nanosatellite vaccine (Q19D) and anti PD-L1 
antibody also show a certain level of tumor suppression. c) The details of tumor growth curves from 
figure b were plotted individually.    
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Figure 4.10. The tumor tissues from mice with different treatments were harvested. Tumor tissues 
from mice were randomly selected from each group of the treatments and the western blotting was 
performed. Nanosatellite vaccine and anti PD-L1 stimulate STING pathway as shown by the increase 
in the phosphorylation of TBK1, p65, and IRF3 proteins, which can subsequently promote type-I IFN 
production.  
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CHAPTER 5 
CONCLUSIONS, SIGNIFICANCES, AND FUTURE PERSPECTIVES 
	
The work presents in this dissertation mainly focuses on the developments and 
applications of structures made from gold and iron oxide nanoparticles. We investigate 
the mechanism to control the formation of secondary structures and fabricate two 
different types of the secondary structures, asymmetrical Janus and symmetrical 
nanosatellite structures. Additionally, we demonstrate the applications of our secondary 
nanostructures for enhanced photothermal effect and drug delivery.  
We also focus on using two different polymers, thermo-cleavable polymer and 
poly (g-MPS-b-PEO), for different structure formations. The thermo-cleavable polymer is 
used to form asymmetrical Janus structure formation in chapter 2. We then further 
studied the utilization of the thermo-cleavable polymer for controlled drug and 
nanoparticle release in chapter 3. The poly (g-MPS-b-PEO) is used to form nanosatellite 
structures in chapter 4.  
 In chapter 2, we report the multi-building block Janus nanostructure formation by 
seed-mediated self-assembly method. This method is reported for the first time by our 
group. This novel thermo-cleavable inducing self-assembly overcomes limitations of 
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current multi-building block Janus manufacturing. This novel method is both simple and 
scalable. We use AuNP and IONP as a proof of concept for the multi-building block 
Janus production; however, this method can potentially be used for other types of 
inorganic nanoparticles such as quantum dots or silica particles. We then further 
explored the unique applications of the formed asymmetrical Janus nanostructures 
(JNS) for enhanced photothermal effect. We hypothesize that the proximity between the 
nanoparticles synergize the cumulative and Coulomb effects generating electron clouds 
in JNS. The data indicate strong temperature increase of the JNS over control than 
other controls after NIR laser light irradiation. The uneven temperature distribution on 
the surface of JNS is due to different light absorption capacity, making the JNS rotate 
actively under NIR light as measured by optical tweezers. The exceptionally active 
Brownian motion of the JNS raise the possibility of a fuel-free Janus motor for cargo 
delivery. Most previously reported Janus motors required fuel such as hydrogen 
peroxide or strong acid to react with the particles to generate the gas for propulsion; 
hence, these fuel-required Janus motors have very limited bio-medical applications. 
Conversely, our Janus motor’s active motion is precisely driven by the NIR laser light, 
which acts as an on-off switch. However, improved techniques to examine and detect 
the Janus motor movement are required for future studies, and we acknowledge the 
lack of sensitivity and accuracy of today’s technology for a nanoscale Janus motor 
motion tracking. In summary, the multi-building block Janus formed by temperature-
triggered self-assembly is a good candidate for photothermal therapy, and represents a 
potential avenue for future fuel-free Janus motors.  
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In chapter 3, we continued investigating the use of the thermo-cleavable polymer 
to control drug release system. We found that IONP co-encapsulated with Dox in the 
thermo-cleavable micelles can be released after NIR laser trigger. This method 
represents an on-demand drug release. IONP function as a photothermal converter 
generating heat, which subsequently disrupts the micelles and releases both Dox and 
IONP at the same time. We expect that the released IONP, which have smaller size 
than the whole micelles, can penetrate deeper into tumor mass. A second treatment of 
the photothermia may eradicate the deep tumor mass. This NIR-triggered drug release 
can be used to treat inoperable metastatic tumors. Although deeper investigations of 
NIR laser-triggered drug release method in animal models are still required, this 
controlled drug release system may be a source of hope for inoperable metastatic 
cancer treatment. 
In chapter 4, another secondary structure made from AuNP and IONP is 
highlighted in addition to the asymmetrical secondary Janus structures reported in 
chapter 2. We developed and characterized these nanosatellite structures for vaccine 
delivery. We used HPV+ head and neck cancer as a model for the treatment because 
there is a treatment gap for viral-induce cancer and current HPV vaccines since current 
vaccines have not been approved for the head and neck cancer (HNSCC) treatment. 
More importantly, the number of HPV+ HNSCC patients presently exceeds the number 
of HPV+ cervical cancer patients. Interestingly, there is no public awareness of this 
HPV+ HNSCC and therefore incidence of HPV+ HNSCC is increasing in the future. This 
suggests that there is an urgent need to develop an HPV+ vaccine for HNSCC 
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treatment. Our animal studies show the promising results and it is possible to warrant a 
clinical trial. Although the treatments in our experiments started very early when the 
tumors were comparative smaller than what physicians encounter, this vaccine could be 
used in a combination with or after ionizing radiation or surgery. Moreover, the 
nanosatellite vaccine platform does not only limit the use for the HNSCC treatment but 
also can extend the applications to personalized medicines using a neo antigen 
specifically to an individual patient for the best result.  
Finally, the goals of this thesis are to invent new materials for cancer theranostics 
by using photothermal effect, active rotational motion, controllable drug delivery, or 
stimulate host’s anti-tumor immunity. This thesis underscores the roles of nanoparticles 
for advanced medical applications.    
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APPENDIX A 
GOLD/IRON OXIDE NANOCOMPOSITES FOR DUAL CANCER THERAPY AND 
IMAGINGS 
 
A.1 Abstract  
It has been well-known that one of the most common treatments for cancers is ionizing 
radiation. This method employs gamma rays to generate reactive oxygen species to 
damage DNA strands resulting in suppression of cell proliferation and causing cell 
death. However, the current ionizing radiation lacks of specific target causing damage to 
normal tissues especially repeatedly high dose ionizing radiation treatments. This leads 
to undesirable adverse effects to patients. Recently, photothermal therapy (PTT) has 
gained a lot of attention due to the high efficiency and less invasion. In this study, we 
developed and investigated an ionizing radiation and photothermal effect of the gold 
and magnetic iron oxide nanocomposite micelles (GMC). GMC demonstrate good 
photothermal and enhanced ionizing properties in 4T1 breast cancer cells in vitro. 
Moreover, the GMC also used as an MRI and CT contrast agent.  
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A.2 Introduction 
 
Presently, radiation therapy or ionizing radiation is one of the most commonly used 
techniques in clinical cancer therapy such as breast cancer1, head and neck cancer2, 
and prostate cancer 3. The radiotherapy could be used in a combination with 
chemotherapy or with surgery to increase success rate of treatments4,5. The current 
techniques for ionizing radiation could be divided into two major categories 1) Eternal-
beam radiation therapy in which photon beams are delivered from an external source 
penetrating into the skin and reaching the tumor in the body6.  2) Internal radiation 
therapy or brachytherapy in which the radioactive material is either temporarily or 
permanently placed inside or on the patient body to deliver the radiation to the proximal 
area of disease7.  Unfortunately, the ionizing radiation in either ways is non-specific to 
the tumors. The radiation doses used to kill the tumor cells are not different from those 
killed normal cells. Although the proliferating tumor cells have slightly higher 
mitochondria activity than normal cell, tumor cells develop resistance to the radiation 
over the period of time. As a consequence,  the doses must be increased8. Normal 
tissues exposed to the radiation are unavoidably damaged causing serious side effects 
to the patients. In a decade, several high atomic number particles including gold 
nanoparticles have been intensively studied. These particles can generate Auger 
electrons after being irradiated with photoelectron beams such as gammy or X-rays, 
which subsequently yields high ionization density locally8. These local secondary 
electrons can generate reactive oxygen species and actively interact with DNA strands 
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resulting in DNA damage and halting cell proliferation9. Hainfeld and coworker (2004) 
pioneered the use of gold nanoparticle for radiotherapy. The authors proved that 1-year 
survival rate in tumor-bearing mice treated with 1.9 nm gold nanoparticles and 
radiotherapy was 4.3 times higher than the mice treated with radiotherapy alone at the 
same doses of X-rays. Chang M.Y. and coworkers (2007) showed that 13 nm gold 
nanoparticles induced B16F10 melanoma cell apoptosis in vitro after the cells were 
incubated with the gold nanoparticles and being treated with the radiation10. Roa et al 
(2009) investigated the cell cycles of the radiation-resistant human prostate cancer cells 
after being treated with glucose-coated gold nanoparticles (Glu-AuNP) and radiation. 
The Glu-AuNP and radiation combination treatment accelerated G0/G1 phase but 
arrested G2/M phase resulting in the increase of radio-sensitivity of the cells11. 
Moreover, due to their high atomic number, gold nanoparticles have also been explored 
as a computed tomography (CT) contrast agent. The CT imaging is one of the most 
useful techniques used in clinical practice. The CT contrast agent used currently is 
iodinated compounds, which have very short half-life and iodine itself has lower atomic 
number than gold. Therefore, it is feasible to use gold nanoparticle to improve the 
quality of CT imaging in clinic. In vitro data revealed that pegylated gold nanoparticles 
provided attenuation coefficient 5.7 times higher than a commercial iodinated contrast 
agent12.  
 Besides, photothermal therapy (PTT) has been attracting a great deal of attention 
in a past decade. This technique takes advantages of a photothermal contrast agent to 
convert photons to phonons resulting in the release of heat energy or high temperature. 
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Iron oxide nanoparticles (IONP) and gold nanoshells have been known for their 
photothermal capability. Iron oxide nanoparticles have been reported to generate heat 
energy under magnetic fields or magnetic hyperthermia and NIR laser irradiation or 
photothermal effect. The magnetic and conversion abilities depend upon the crystallinity 
and volume of the particles13–15. Crystalized iron oxide nanoparticles absorb the light at 
near-infrared wavelength, 650-900 nm and emit heat energy16. NIR laser irradiation is 
considered safe for in vivo use under the low laser power because body fluid, such as 
hemoglobin, has low absorption in this wavelength17–19. Similarly, to iron oxide 
nanoparticles, gold nanoshells can also absorb the near infrared light and emit phonon. 
Gold nanoshells have gained a lot of attention since last a decade and have been being 
investigated in a clinical trial for head and neck cancer, and lung cancer treatment. 
However, there is still a serious concern about their safety and accumulation in the 
body. The sizes of gold nanoshells generally vary from 10-200 nm with silicon shell, 
which has very limited clearance18. For these reasons, iron oxide nanoparticles may be 
a better alternative choice for PTT because they are biodegradable to endogenous 
substance such as ferric and ferrous.  
 Although small sizes of gold and iron oxide nanoparticles are preferred for both 
radiotherapy and photothermal therapy, they have very rapid clearance. The high doses 
of nanoparticles are required. We propose to use gold/iron oxide micelles, which are 
composed of multiple small gold and iron oxide nanoparticles to prolong the half-life of 
the nanoparticle without compromising the radiation and photothermal properties of the 
small nanoparticles as well as imaging capability.  
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In our study, we explored the dual ability of gold and magnetic iron oxide 
nanoparticle nanocomposite micelles (GMC) for ionizing radiation and PTT in murine 
breast cancer cells as well as imaging properties. Oleic acid-coated iron oxide 
nanoparticles with the size of 15 nm and 2 nm dodecane thiol-coated gold nanoparticles 
co-encapsulated in DA-b-PEO polymeric micelles were synthesized, characterized and 
investigated for in vitro properties.  
A.3 Results and discussion 
A.3.1 Nanoparticles synthesis and characterization 
Hydrophobic dodecane thiol gold nanoparticles (AuNP) were synthesized by a 
previously reported method. The synthesized AuNP have the diameter ca 2 nm 
characterized by transmission electron microscope (TEM) (figure A.1a). The AuNP do 
not have an absorption peak at UV-visible region because the diameter is too small, 
which correspond to the previous report. The AuNPs are stable for over a month after 
synthesis. There is no absorption wavelength shift or a sign of aggregation formation 
(figure A.1b). The DA-b-PEO and 15 nm iron oxide nanoparticles (IONP) were 
synthesized as previously mentioned in Chapter 2. AuNP and IONP were encapsulated 
together in DA-b-PEO polymeric micelles. TEM images suggest that AuNP and IONP 
formed dense random clusters inside the micelles due to a hydrophobic interaction 
(figure A.1d and e). Hydrodynamic diameter of the gold and magnetic iron oxide 
micelles (GMC) is 172.7 nm with polydispersity index 0.106 measured by a dynamic 
light scattering method (figure A.1f).   
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A.3.2 Enhanced nanoparticle uptake, Photothermal effect, and ionizing radiation 
We investigated the cell uptake of the GMC in a normal incubation condition and 
acceleration condition under the magnet. 4T1 murine breast cancer cells were 
incubated with the GMC with or without a magnet under the cell culture plates at 
different time points. The data suggest that the cell uptake of the gold and iron in 4T1 
cells is increasing at 2, 4, and 6 hours after incubation. The concentrations of gold in 
4T1 cells increase to 1.4, 6.4, and 3.1 times higher than the concentration of gold in 
GMC without the magnet acceleration at 2, 4, and 6 hours, which agrees with the 
concentration of iron in the cells at the same time points. The concentrations of iron 
increase up to 1.8, 4.2, and 4.4 times higher than those without acceleration by a 
magnet (figure A.2). This suggest that the concentration AuNP uptaken into the cells 
could be enhanced by the magnet acceleration because the AuNP were encapsulated 
together with IONP in micelles. When the magnet induces the cell uptake of IONP, the 
AuNP are also internalized into the cells simultaneously. The increase of cell uptake of 
AuNP is important for ionizing radiation and CT scan because the theranostics of AuNP 
require very high dose of AuNP. In vivo intravenous dose of 1.9 nm gold nanoparticles 
used for ionizing radiation is extremely high (2.7g/kg)20 and 4g/kg for CT imaging21. 
However, the dose of AuNP used for ionizing radiation and CT imaging can be reduced 
with the magnet-enhanced cell uptake of GMC.  
A.3.3 Photothermal effect of GMC 
The photothermal efficacy of GMC was investigated using a NIR laser, 885 nm, 
1W/cm2, with the spot 5x8 mm. 10 minutes after the laser irradiation, the temperature of 
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the media containing GMC increased 42.9 °C from the initial temperature, while the 
temperature increase of the water control was only 9.4 °C. The IONP micelles were also 
used as a positive control to compare whether the insertion of AuNP into the IONP in 
the GMC disrupts the photothermal efficacy of IONP in the GMC. The IONP micelles 
raised 51 °C from the initial temperature, which is relatively higher than GMC at the 
same concentration of Fe (figure A.3a). There are two possibilities of the different 
temperature increase between the GMC and IONP at the same concentration of Fe. 
First, the insertion of AuNP between the IONP may disrupt the ability of IONP to convert 
photons to phonons and the release of phonon to the media. Second, Au interferes 
absorption wavelength of IONP when the concentration of Fe was measures by 
colorimetric methods. This can create an error in Fe concentration calculation in GMC, 
which turn into overestimate the concentration of Fe in the sample. In this case, we 
used 2 nm AuNP, which cannot contribute to the temperature increase because the size 
of AuNP are too small and do not have absorption at UV-VIS and NIR regions22,23 
(figure 3b). This agrees with previous reports. However, the data suggest that GMC can 
generate high temperature after NIR laser irradiation due to IONP and GMC could be 
used as photothermal contrast agent at NIR wavelength.  
A.3.4 Ionizing radiation effect of GMC in breast cancer cells  
We performed clonogenic assays to determine the effect of GMC in enhancing 
radiotherapy and DNA damage in 4T1 murine breast cancer cell lines. 4T1 cells were 
incubated with GMC or cell culture media overnight. The cells were washed twice 
before the radiation treatments. The cells were subsequently treated with an X-rays 
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ionizing radiation source, 320 kV, at 2, 4, and 6 Gy. The colony formations were 
monitored for 7 days. The data demonstrate that GMC enhance the sensitization of 
radiotherapy at 4 and 6 Gy. The cell survival fractions decrease 4.33-fold and 4.25-fold 
at 4 and 6 Gy respectively; although, there was no different in survival fraction at 2 Gy 
because the dose is too low to sensitize the ejection of electrons on Au shells (figure 4). 
The previous studies also reported the similar effect at the dose of 2 Gy with low 
concentration of AuNP22,24. The enhanced sensitization of the radiotherapy can 
dramatically improve the treatment and minimize the adverse effects of high dose 
radiation treatments. The enhanced sensitization of radiation by AuNP results from first, 
the exponential release of Auger electrons from shells of Au atom after being triggered 
by the radioactive source causing a vast generation of reactive radical species locally. 
Second, the AuNP internalized into the cells and colocalized at the cytosolic membrane 
and endosome, which have a proximal distance to the nucleus, leading to the higher 
DNA damage and affect cell proliferation and apoptosis10,25,26.  However, the in vivo 
intravenous dose of 1.9 nm gold nanoparticles used for ionizing radiation is extremely 
high (2.7g/kg) due to rapid renal clearance of the small gold nanoparticles. The time to 
peak of the tumor accumulation was 5 minutes after IV injection20,27. In order to avoid 
the rapid clearance of small AuNP, GMC could become a new alternative because the 
size of GMC is large enough to stay longer in body. Nevertheless, we hypothesize that 
after endosomal uptake in a cellular level, GMC could be degraded into small AuNP and 
excrete out of the body, while IONP in GMC could be metabolized into ferric and 
ferrous.  
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A.3.5 In vitro MRI and CT imaging of GMC   
A computed tomography (CT) imaging are widely used in current clinical practice to 
cancer diagnosis. One of the most commonly used CT contrast agent is Iodine due to 
the high atomic number. AuNP are also a great candidate for CT imaging as Au atom 
has higher atomic number than Iodine. The X-ray beams exciting the electrons of Au 
atom to ionize cause resonance absorption from atom in the medium and increase the 
absorption coefficient of the medium28. AuNP yield a far higher attenuation of an X-ray 
beam than Iodine at the similar thickness and concentration29. We then examined the 
use of GMC for in vitro CT imaging. We first compared the CT imaging capability of Au 
micelles and our GMC to determine whether the insertion of IONP impact the ability of 
AuNP for CT imaging at the same concentration of Au. The data indicate the phantom 
CT images between the Au micelles and GMC have relatively similar contrast (figure 
5a). We also determined the linear transformation of the measured attenuation 
coefficients demonstrating as Hounsfield unit (HU) based on the radiodensity of distilled 
water at standard pressure and temperature. The increased linear transformation for CT 
imaging using AuNP as a contrast agent began at the concentration of Au 0.5 mg/ml in 
both GMC and Au micelles (figure 5b). However, there was no significant different of the 
CT contrast between GMC and Au micelles, implying that GMC could be used as the 
CT contrast media similar to AuNP.  
 Another imaging technique widely used in hospital setting is magnetic resonance 
imaging (MRI). MRI provides a safer technique and higher resolution images compared 
to CT scan. IONP have been intensively studied for MRI as they can lower T2 relaxation 
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resulting better contrast images. In our report, we determine if our GMC could be used 
for MRI. The phantom MRI shows that the GMC can clearly darken the solution 
providing a better contrast (figure 6a). Moreover, T2 relaxivity of GMC is very high, 285 
mM-1.S-1, which is much higher than the T2 relaxivity of a commercial brand, Feridex, 
98.3 mM-1.S-1 (figure 6b).  
A.4 Conclusion 
In this study, we developed gold/iron oxide nanoparticles encapsulated in polymeric 
micelles. GMC exhibit strong imaging properties for both CT and MRI, which is very 
useful for cancer diagnosis. Dual imaging can also be performed at the same time to 
increase the accuracy of tumor position and size. For treatments, these micelles 
demonstrate the enhanced ionizing radiation (IR) proved by the clonogenic assay. GMC 
also show a great photothermal property under NIR light. The temperature increases 
dramatically after NIR light trigger. Therefore, GMC is a very promising agent used for 
dual treatment for both ionizing radiation and photothermal therapy (PTT). We expect 
that the dual therapy of IR and PTT will improve the effectiveness of cancer treatment; 
however, more studies are needed.  
A.5 Materials and methods 
Materials: furfuryl alcohol (98%), triethanolamine (TEA,99%), dioxane (99.5%, extra 
dry), and1,1,2,2 tetrachloro ethane (TCE,98.5%) were purchased from Acros Organics. 
Petroleum ether (certified ACS grade), and dichloromehane (certified ACS grade) were 
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purchased from Fisher Scientific. Ethyl acetate (anhydrous, 99.8%), tetrahydrofuran 
(THF, anhydrous 99.8%), adipoyl chloride, bismaleimido diphynyl methane (BMD), Gold 
(III) chloride solution (99.99%), 1-dodecanethiol (98%), Tetraoctylammonium bromide 
(98%), Sodium borohydride, and dimethyl sulfoxide (DMSO, 99.5%) were purchased 
from Sigma-Aldrich. Thiol methoxy polyethylene oxide 5KDa was purchased from 
NanoCS. Doxorubicin HCl (99.5%) was purchased from Polymed therapeutics.  
 
Synthesis of 2nm dodecenethiol gold nanoparticles: Two-phase method was 
used to synthesized 2nm dodecenethiol gold nanoparticles as reported by previous 
literature30,31. Briefly, an aqueous solution of gold (III) chloride solution (30mM) was 
homogeneously mixed with tetraoctylammonium bromide (50mM) in toluene. After the 
toluene phase became orange, the aqueous phase was discarded. Dodecanethiol 
(2mmol) was added into the toluene phase following by slowly dropping sodium 
borohydride (0.4M, 25 ml). The solution was stirred rigorously. The color of the solution 
changed from orange to deep brown within a few minutes. After the solution was stirred 
for 3 hours, the organic phase was separated and evaporated in rotation evaporator. 
The product was washed 3 times in 200 ml of ethanol to get rid of excess 
dodecenethiol.   
Synthesis of homogeneous Au/IONP micelles (GMC): Oleic acid coated-IONPs 
(1mg) and dodecanethiol AuNPs (1 mg) were dissolved together in THF and 
subsequently added into 20 mg of DA-b-PEO solution in THF under stirring. The 
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resulting solution was slowly dropped into water under vigorous agitation. The product 
was purified twice by weight-separated centrifugation.  
Characterization of nanoparticle: TEM imaging were prepared by the solvent 
evaporation method. Briefly, the solution (5 µL) of each sample were dropped onto 
carbon-coated copper TEM grids and allowed to dry overnight. TEM images were 
acquired on a transmission electron microscope (TEM, Phillips CM-100, 60 kV). 
Hydrodynamic diameters were measured by using Malvern Zeta Sizer Nano S-90. 
Concentrations of Au were quantified by Inductively Coupled Plasma - Optical Emission 
Spectroscopy (ICP-OES) (Perkin-Elmer Optima 2000 DV). The samples were digested 
in aqua regia overnight before measurement. Concentration of Fe was measured by 
colorimetric method. Briefly, 10 mL of GMC was digested in concentrated HCl solution. 
After two days, sodium citrate was added to adjust the solution pH to 3.5. Then 2 mL of 
hydroquinone (10 g/l) and 3mLof o-phenanthroline (2.5 g in 100 mL of ethanol and 900 
mL of water) were added to the solution followed by adjusting to a specific volume using 
Milli-Q water. Five standard Fe solutions using Fe(NH4)2(SO4)2.6H2O were also made. 
To determine the solution concentration of iron, calibration curves were generated by 
measuring the optical absorbance of solutions at 508 nm. 
Cell uptake study: 4T1 murine breast cancer cell were seeded in 6-well plates at 
the density of 0.45 million cells/plate. The cells were incubate at 37 °C overnight and 
next day GMC (50nM) were incubated with the cells with or without magnet-induce cell 
uptake. The cells were washed twice by phosphate buffer saline (PBS) and digested 
151	
	
with aqua regia at 2, 4, and 6 hours for elemental analysis by ICP-OES. Standard 
curves for Au and Fe were generated using Yitrium as an internal standard.  
Photothermal effect: IONP and GMC (0.2 mg/ml Fe, 100 ul) in aqueous media 
were exposed to NIR laser light 885 nm, 2.5 W/cm2, spot size 5x8 mm. The temperature 
of the solutions was measured using a thermal camera (FLIR, Boston, MA). 
Clonogenic assay: 4T1 were seeded at 5x104 cells/well in 6-well plates overnight 
to allow the cells attach to the plates. Next day, the cells were incubated with GMC or 
PBS. After 24 hours, the cells were irradiated at 2, 4, 6 Gy or mock radiation using X-
rays orthovoltage 320kV. After the radiation, the cells were washed twice with PBS, 
trypsinized and seeded according to the radiation doses 0, 2, 4, and 6 Gy at the density 
of 100, 250, 1000, and 4000 cells/well in 6-well plates. The cells were maintained in 37 
°C, 5% CO2 for 7 days without changing media. The cells were then fixed with 
methanol: acetic acid 7:1 and stained with crystal violet. The colonies that contain ³ 50 
cells were counted. The surviving fraction was calculated as (colonies counted)/(cells 
seeded x (plating efficiency/100)). Each point on the survival curve were done in 
triplicate.  
Phantom CT imaging: CT images were performed using Siemens Inveon with Au 
micelles or GMC at the concentration of Au 0, 0.1, 0.5, 1, and 2 mg/ml. Air was used to 
set the radiosensitivity at standard temperature and pressure as -1000 HU. The images 
were collected and the linear transformation of the measured attenuation coefficients 
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was calculated using an in-house software provided by Center for Molecular Imaging 
(CMI), University of Michigan.  
Phantom magnetic resonance imaging: GMC at the concentration of Fe at 0, 
0.018, 0.036, 0.09, 0.143, and 0.18 mM were constructed for MRI, T2 mapping, and R2 
relaxivity. A multiecho fast spin-echo was used to simultaneously collect a series of data 
points at different echo times (TE = 15–90 ms with an increment of 15 ms). AN in-house 
software was used to calculated R2 relaxivity.  
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Figure A.1. a) a TEM image of 2nm dodecenethiol-coated AuNP synthesis by two-phase method. b) 
absorption spectra of freshly prepared and a month after prepared dodecenethiol-coated AuNP. The 
absorption spectra remain the same after one month of storage at 4 °C indicating a good stability of the 
dodecenethiol AuNP. 2 nm AuNP lack of absoption peak at 520 nm due to ultra small size. c) The chart 
shows hydrodynamic diameter of GMC ca 172.7 nm with PDI 0.106. The size of freshly prepared GMC 
and after being stored for a month are similar suggesting that GMC is stable for over a month. d) a 
TEM image of GMC demonstrates a homogeneously mixed between 2 nm AuNP and 15 nm IONP in 
GMC. e) a high magnification of GMC. AuNP and IONP form a cluster inside a hydrophobic core of the 
polymer.   
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Figure A.2. a) and b) calibration curves of standard Au and Fe measured by ICP-OES. c) The graph 
shows the fold of the amount cell uptake of Au and Fe from GMC. The fold changes were calculated by 
the amount of the determined elements found in the cells induced by magnet divided by the amount of 
the determined elements found in the cells without magnet induction. The amount of Au is enhanced by 
the magnet induction because the AuNP were encapsulated in the same micelles with IONP. The peak 
time of magnet-induce Au uptake is at 4 hours. The amount of Au in cells was 6.4-fold higher with 
magnet induction compared to no magnet induction. 
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Figure A.3. a) The photothermal effect of IONP micelles, GMC, and water control during 10 
minutes of NIR laser light irradiation at 885 nm, 2.5 W/cm2 with a spot size of 5x8 mm. b) the 
absorption spectra of IONP and AuNP. IONP can absorb the NIR light, while 2 nm AuNP lack of 
light absorption. 
Figure A.4. The chart presents the surviving fraction of clonogenic assays at different irradiation 
doses. The data suggest that GMC at the concentration of Au 0.1 mg/ml enhance cell death after 
radiation treatment at dose 4, and 6 Gy.  
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Figure A.5. Phantom CT scans of Au micelles and GMC at the same concentration of Au. a) Both 
GMC and Au micelles provide good contrast images indicating that the insertion of IONP in GMC 
does not impact the CT imaging property of AuNP. b) The linear transformation of the measured 
attenuation coefficients demonstrating as Hounsfield unit (HU) based on the radiodensity of distilled 
water at standard pressure and temperature. The increased linear transformations for CT imaging 
between Au micelles and GMC are relatively close and significantly different from water at the 
concentration of Au is equal to 0.5 mg/ml.  
Figure A.6. GMC as an MRI contrast agent. a) A phantom MRI images at different concentration 
of Fe in GMC. The images show that GMC can increase the contrast of the solution in a Fe 
concentration dependence. b) The R2 relaxivity was calculated from the T2 relaxation of the 
solution.   
